{
  "file_name": "CUAD_v1/full_contract_pdf/Part_I/Promotion/DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement.pdf",
  "annotations": [
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "CO-PROMOTION AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ],
          "confidence": 0.9996495842933655
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Valeant",
      "page_number": 0,
      "words": [
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ],
          "confidence": 0.9993768334388733
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Dova Pharmaceuticals, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ],
          "confidence": 0.9989398121833801
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Dova",
      "page_number": 0,
      "words": [
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ],
          "confidence": 0.9989398121833801
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Dova and Valeant are each referred to individually as a \"Party\" and together as the \"Parties\".",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2800.0,
            283.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9779579043388367
        },
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ],
          "confidence": 0.9996495842933655
        },
        {
          "text": "by and between",
          "bbox": [
            1477.0,
            872.0,
            1834.0,
            915.0
          ],
          "confidence": 0.9997774958610535
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ],
          "confidence": 0.9989398121833801
        },
        {
          "text": "and",
          "bbox": [
            1605.0,
            1278.0,
            1701.0,
            1331.0
          ],
          "confidence": 0.9980132579803467
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ],
          "confidence": 0.9993768334388733
        },
        {
          "text": "September 26, 2018",
          "bbox": [
            1419.0,
            1637.0,
            1883.0,
            1692.0
          ],
          "confidence": 0.9950999021530151
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ],
          "confidence": 0.989909827709198
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ],
          "confidence": 0.994059681892395
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9876725673675537
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Valeant Pharmaceuticals North America LLC",
      "page_number": 0,
      "words": [
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ],
          "confidence": 0.9993768334388733
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "September 26, 2018",
      "page_number": 0,
      "words": [
        {
          "text": "September 26, 2018",
          "bbox": [
            1419.0,
            1637.0,
            1883.0,
            1692.0
          ],
          "confidence": 0.9950999021530151
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Effective Date_7",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective ",
      "answer_text": "\"Effective Date\" shall have the meaning set forth in the preamble to this Agreement.",
      "page_number": 7,
      "words": [
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        }
      ],
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Effective Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective ",
      "answer_text": "September 26, 2018",
      "page_number": 0,
      "words": [
        {
          "text": "September 26, 2018",
          "bbox": [
            1419.0,
            1637.0,
            1883.0,
            1692.0
          ],
          "confidence": 0.9950999021530151
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Expiration Date_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "This Agreement shall become effective as of the Effective Date and, unless earlier terminated as provided in this ARTICLE 12, shall extend until the four (4) year anniversary of the Effective Date (the \"Term\").",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Expiration Date_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "This Agreement shall become effective as of the Effective Date and, unless earlier terminated as provided in this ARTICLE 12, shall extend until the four (4) year anniversary of the Effective Date (the \"Term\").",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Governing Law_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the internal laws of the [***] applicable to agreements made and to be performed entirely in such state, including its statutes of limitation but without giving effect to the conflict of law principles thereof.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Governing Law_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the internal laws of the [***] applicable to agreements made and to be performed entirely in such state, including its statutes of limitation but without giving effect to the conflict of law principles thereof.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Non-Compete_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector? ",
      "answer_text": "[***], neither Valeant nor its Affiliates shall, directly or indirectly, [***] in the Territory other than the Product; provided that if the Agreement is terminated by Dova pursuant to [***], then any Tail Period shall be immediately terminated if either Valeant or any of its Affiliates, directly or indirectly, [***] in the Territory other than the Product during such Tail Period.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Non-Compete_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector? ",
      "answer_text": "[***], neither Valeant nor its Affiliates shall, directly or indirectly, [***] in the Territory other than the Product; provided that if the Agreement is terminated by Dova pursuant to [***], then any Tail Period shall be immediately terminated if either Valeant or any of its Affiliates, directly or indirectly, [***] in the Territory other than the Product during such Tail Period.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2800.0,
            283.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9779579043388367
        },
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ],
          "confidence": 0.9996495842933655
        },
        {
          "text": "by and between",
          "bbox": [
            1477.0,
            872.0,
            1834.0,
            915.0
          ],
          "confidence": 0.9997774958610535
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ],
          "confidence": 0.9989398121833801
        },
        {
          "text": "and",
          "bbox": [
            1605.0,
            1278.0,
            1701.0,
            1331.0
          ],
          "confidence": 0.9980132579803467
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ],
          "confidence": 0.9993768334388733
        },
        {
          "text": "September 26, 2018",
          "bbox": [
            1419.0,
            1637.0,
            1883.0,
            1692.0
          ],
          "confidence": 0.9950999021530151
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ],
          "confidence": 0.989909827709198
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ],
          "confidence": 0.994059681892395
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9876725673675537
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ],
          "confidence": 0.9780283570289612
        },
        {
          "text": "Page",
          "bbox": [
            2776.0,
            688.0,
            2901.0,
            750.0
          ],
          "confidence": 0.9999327659606934
        },
        {
          "text": "1",
          "bbox": [
            2864.0,
            917.0,
            2902.0,
            968.0
          ],
          "confidence": 0.9995635151863098
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ],
          "confidence": 0.9859031438827515
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ],
          "confidence": 0.9988932013511658
        },
        {
          "text": "8",
          "bbox": [
            2864.0,
            1029.0,
            2902.0,
            1082.0
          ],
          "confidence": 0.9996312856674194
        },
        {
          "text": "2.1 Engagement; Grant of Rights.",
          "bbox": [
            254.0,
            1142.0,
            1035.0,
            1193.0
          ],
          "confidence": 0.9930101633071899
        },
        {
          "text": "8",
          "bbox": [
            2866.0,
            1142.0,
            2904.0,
            1193.0
          ],
          "confidence": 0.9996554851531982
        },
        {
          "text": "2.2 Retention of Rights.",
          "bbox": [
            255.0,
            1255.0,
            803.0,
            1305.0
          ],
          "confidence": 0.9952546954154968
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1254.0,
            2902.0,
            1305.0
          ],
          "confidence": 0.99913090467453
        },
        {
          "text": "2.3 Non-Competition; Non-Solicitation.",
          "bbox": [
            255.0,
            1369.0,
            1155.0,
            1416.0
          ],
          "confidence": 0.9856934547424316
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1365.0,
            2902.0,
            1418.0
          ],
          "confidence": 0.9992173910140991
        },
        {
          "text": "2.4 Dova Trademarks and Copyrights.",
          "bbox": [
            256.0,
            1482.0,
            1135.0,
            1528.0
          ],
          "confidence": 0.9905837178230286
        },
        {
          "text": "10",
          "bbox": [
            2837.0,
            1476.0,
            2904.0,
            1531.0
          ],
          "confidence": 0.9995734095573425
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ],
          "confidence": 0.9954172968864441
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1592.0,
            2900.0,
            1641.0
          ],
          "confidence": 0.9997044801712036
        },
        {
          "text": "3.1 Formation of the JSC.",
          "bbox": [
            256.0,
            1707.0,
            839.0,
            1751.0
          ],
          "confidence": 0.992499589920044
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1705.0,
            2900.0,
            1754.0
          ],
          "confidence": 0.9998102188110352
        },
        {
          "text": "3.2 Meetings and Minutes..",
          "bbox": [
            255.0,
            1818.0,
            877.0,
            1866.0
          ],
          "confidence": 0.9774132370948792
        },
        {
          "text": "11",
          "bbox": [
            2840.0,
            1813.0,
            2902.0,
            1868.0
          ],
          "confidence": 0.9997932314872742
        },
        {
          "text": "3.3 Purpose of the JSC",
          "bbox": [
            256.0,
            1933.0,
            790.0,
            1975.0
          ],
          "confidence": 0.9881646633148193
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1928.0,
            2900.0,
            1977.0
          ],
          "confidence": 0.9997947812080383
        },
        {
          "text": "3.4 Decision Making..",
          "bbox": [
            252.0,
            2035.0,
            751.0,
            2094.0
          ],
          "confidence": 0.954731285572052
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2037.0,
            2904.0,
            2090.0
          ],
          "confidence": 0.9999567270278931
        },
        {
          "text": "3.5 Marketing Sub-Committee.",
          "bbox": [
            255.0,
            2154.0,
            972.0,
            2204.0
          ],
          "confidence": 0.9678689241409302
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2151.0,
            2902.0,
            2204.0
          ],
          "confidence": 0.9999614953994751
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ],
          "confidence": 0.999039351940155
        },
        {
          "text": "14",
          "bbox": [
            2838.0,
            2262.0,
            2904.0,
            2315.0
          ],
          "confidence": 0.9999129176139832
        },
        {
          "text": "4.1 Valeant Activities.",
          "bbox": [
            254.0,
            2379.0,
            756.0,
            2427.0
          ],
          "confidence": 0.9994301199913025
        },
        {
          "text": "14",
          "bbox": [
            2835.0,
            2376.0,
            2904.0,
            2429.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "4.2 Detailing.",
          "bbox": [
            251.0,
            2485.0,
            561.0,
            2544.0
          ],
          "confidence": 0.947688102722168
        },
        {
          "text": "15",
          "bbox": [
            2837.0,
            2485.0,
            2904.0,
            2542.0
          ],
          "confidence": 0.9998620748519897
        },
        {
          "text": "4.3 Compliance with Applicable Law.",
          "bbox": [
            254.0,
            2604.0,
            1097.0,
            2652.0
          ],
          "confidence": 0.999403178691864
        },
        {
          "text": "17",
          "bbox": [
            2837.0,
            2598.0,
            2904.0,
            2653.0
          ],
          "confidence": 0.9998419284820557
        },
        {
          "text": "4.4 Field Force Personnel Training; Product Materials..",
          "bbox": [
            256.0,
            2717.0,
            1515.0,
            2761.0
          ],
          "confidence": 0.9813730120658875
        },
        {
          "text": "19",
          "bbox": [
            2835.0,
            2712.0,
            2904.0,
            2765.0
          ],
          "confidence": 0.9997812509536743
        },
        {
          "text": "4.5 Provisions Related to Field Force Personnel",
          "bbox": [
            254.0,
            2829.0,
            1367.0,
            2874.0
          ],
          "confidence": 0.999675989151001
        },
        {
          "text": "21",
          "bbox": [
            2835.0,
            2825.0,
            2900.0,
            2878.0
          ],
          "confidence": 0.9999203681945801
        },
        {
          "text": "4.6 Responsibility for Valeant Activity Costs and Expenses..",
          "bbox": [
            256.0,
            2940.0,
            1628.0,
            2988.0
          ],
          "confidence": 0.983078122138977
        },
        {
          "text": "22",
          "bbox": [
            2835.0,
            2937.0,
            2902.0,
            2990.0
          ],
          "confidence": 0.9998236894607544
        },
        {
          "text": "4.7 Data Sharing.",
          "bbox": [
            252.0,
            3048.0,
            653.0,
            3105.0
          ],
          "confidence": 0.975680947303772
        },
        {
          "text": "22",
          "bbox": [
            2838.0,
            3052.0,
            2900.0,
            3099.0
          ],
          "confidence": 0.9997785091400146
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ],
          "confidence": 0.9930562376976013
        },
        {
          "text": "MATTERS",
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ],
          "confidence": 0.999487042427063
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3231.0,
            2902.0,
            3286.0
          ],
          "confidence": 0.999907374382019
        },
        {
          "text": "5.1 Dova Responsibility",
          "bbox": [
            256.0,
            3349.0,
            814.0,
            3395.0
          ],
          "confidence": 0.9984672665596008
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3342.0,
            2902.0,
            3397.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "5.2 Valeant Involvement.",
          "bbox": [
            256.0,
            3463.0,
            827.0,
            3503.0
          ],
          "confidence": 0.9985610842704773
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3456.0,
            2902.0,
            3508.0
          ],
          "confidence": 0.9999406337738037
        },
        {
          "text": "23",
          "bbox": [
            2834.0,
            3564.0,
            2904.0,
            3624.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "5.3 Inspections.",
          "bbox": [
            256.0,
            3576.0,
            609.0,
            3620.0
          ],
          "confidence": 0.9983316659927368
        },
        {
          "text": "5.4 Pharmacovigilance.",
          "bbox": [
            254.0,
            3684.0,
            783.0,
            3732.0
          ],
          "confidence": 0.9932737946510315
        },
        {
          "text": "24",
          "bbox": [
            2837.0,
            3680.0,
            2904.0,
            3733.0
          ],
          "confidence": 0.9999386668205261
        },
        {
          "text": "5.5 Unsolicited Requests for Medical Information.",
          "bbox": [
            254.0,
            3797.0,
            1414.0,
            3843.0
          ],
          "confidence": 0.9851503372192383
        },
        {
          "text": "24",
          "bbox": [
            2835.0,
            3792.0,
            2904.0,
            3845.0
          ],
          "confidence": 0.9999282956123352
        },
        {
          "text": "5.6 Recalls and Market Withdrawals",
          "bbox": [
            257.0,
            3911.0,
            1115.0,
            3953.0
          ],
          "confidence": 0.9952821135520935
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            3903.0,
            2904.0,
            3958.0
          ],
          "confidence": 0.9998209476470947
        },
        {
          "text": "5.7 Certain Reporting Responsibilities",
          "bbox": [
            256.0,
            4026.0,
            1153.0,
            4068.0
          ],
          "confidence": 0.9995793700218201
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4017.0,
            2904.0,
            4069.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "5.8 Booking of Sales Revenues.",
          "bbox": [
            254.0,
            4132.0,
            993.0,
            4181.0
          ],
          "confidence": 0.9986859560012817
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4128.0,
            2904.0,
            4183.0
          ],
          "confidence": 0.9998403787612915
        },
        {
          "text": "5.9 Returns.",
          "bbox": [
            253.0,
            4243.0,
            539.0,
            4295.0
          ],
          "confidence": 0.9989113807678223
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4239.0,
            2904.0,
            4296.0
          ],
          "confidence": 0.9997888803482056
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9973026514053345
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ]
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "page": 1,
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ]
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "page": 1,
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ]
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "page": 1,
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ]
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "page": 1,
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ]
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "page": 1,
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ]
        },
        {
          "text": "MATTERS",
          "page": 1,
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Competitive Restriction Exception_7",
      "question": "Highlight the parts (if any) of this contract related to \"Competitive Restriction Exception\" that should be reviewed by a lawyer. Details: This category includes the exceptions or carveouts to Non-Compete, Exclusivity and No-Solicit of Customers above.",
      "answer_text": "Notwithstanding anything to the contrary, in no event shall the restrictions set forth in this Section 2.3.2 apply to [***].",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Competitive Restriction Exception_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Competitive Restriction Exception\" that should be reviewed by a lawyer. Details: This category includes the exceptions or carveouts to Non-Compete, Exclusivity and No-Solicit of Customers above.",
      "answer_text": "Notwithstanding the foregoing, this Section 2.3.1(a) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons, [***].",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Competitive Restriction Exception_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Competitive Restriction Exception\" that should be reviewed by a lawyer. Details: This category includes the exceptions or carveouts to Non-Compete, Exclusivity and No-Solicit of Customers above.",
      "answer_text": "Notwithstanding the foregoing, this Section 2.3.1(a) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons, [***].",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__No-Solicit Of Employees_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party’s soliciting or hiring employees and/or contractors from the  counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "[***], neither Valeant nor Dova (nor any of their respective Affiliates) shall directly or indirectly solicit for hire or employee as an employee, consultant or otherwise any of the other Party's professional personnel who have had direct involvement with the JSC, with the Valeant Activities under this Agreement (which, in the case of Valeant, includes the Field Force Personnel) or with Dova's commercialization activities for the Product, without the other Party's prior written consent.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__No-Solicit Of Employees_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party’s soliciting or hiring employees and/or contractors from the  counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "[***], neither Valeant nor Dova (nor any of their respective Affiliates) shall directly or indirectly solicit for hire or employee as an employee, consultant or otherwise any of the other Party's professional personnel who have had direct involvement with the JSC, with the Valeant Activities under this Agreement (which, in the case of Valeant, includes the Field Force Personnel) or with Dova's commercialization activities for the Product, without the other Party's prior written consent.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Termination For Convenience_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this  contract without cause (solely by giving a notice and allowing a waiting  period to expire)?",
      "answer_text": "Either Party shall have the right to terminate this Agreement before the end of the Term for its convenience upon [***] written notice to the other Party (and any such termination shall become effective at the end of such [***]); [***].",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Termination For Convenience_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this  contract without cause (solely by giving a notice and allowing a waiting  period to expire)?",
      "answer_text": "Either Party shall have the right to terminate this Agreement before the end of the Term for its convenience upon [***] written notice to the other Party (and any such termination shall become effective at the end of such [***]); [***].",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Change Of Control_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Notwithstanding the foregoing, (a) either Party may, without the other Party's consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or other transfer of all or substantially all of Dova's assets or rights relating to the Product; provided that such assignee shall remain subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing before or after such assignment.",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Change Of Control_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Notwithstanding the foregoing, (a) either Party may, without the other Party's consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or other transfer of all or substantially all of Dova's assets or rights relating to the Product; provided that such assignee shall remain subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing before or after such assignment.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Anti-Assignment_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "In the event either Party desires to make such an assignment or other transfer of this Agreement or any rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party's written consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination whether to provide such written consent within [***] following its receipt of such written notice from such Party.",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Anti-Assignment_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "In the event either Party desires to make such an assignment or other transfer of this Agreement or any rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party's written consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination whether to provide such written consent within [***] following its receipt of such written notice from such Party.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Anti-Assignment_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld); provided that a merger, sale of stock or comparable transaction shall not constitute an assignment.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Anti-Assignment_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld); provided that a merger, sale of stock or comparable transaction shall not constitute an assignment.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Anti-Assignment_7",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except to Affiliates of Valeant, Valeant shall not subcontract the Valeant Activities with any Third Party (including any contract sales force).",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Anti-Assignment_7",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Any attempted assignment not in accordance with this Section 13.2 shall be void.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Revenue/Profit Sharing_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "Commencing with the Calendar Quarter commencing on October 1, 2018, as consideration for the Valeant Activities performed by Valeant, Dova shall pay Valeant a promotion fee based on annual Net Sales during the Term, calculated as follows:\n\n(a) For any portion of Net Sales up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales;\n\n(b) For any portion of Net Sales in excess of [***] and up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales; and\n\n(c) For any portion of Net Sales in excess of [***] in a Calendar Year, [***] of such portion of Net Sales.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Revenue/Profit Sharing_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "Commencing with the Calendar Quarter commencing on October 1, 2018, as consideration for the Valeant Activities performed by Valeant, Dova shall pay Valeant a promotion fee based on annual Net Sales during the Term, calculated as follows:\n\n(a) For any portion of Net Sales up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales;\n\n(b) For any portion of Net Sales in excess of [***] and up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales; and\n\n(c) For any portion of Net Sales in excess of [***] in a Calendar Year, [***] of such portion of Net Sales.",
      "page_number": 8,
      "words": [
        {
          "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
          "bbox": [
            277.0,
            495.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9923841953277588
        },
        {
          "text": "to time.",
          "bbox": [
            276.0,
            566.0,
            433.0,
            612.0
          ],
          "confidence": 0.9964673519134521
        },
        {
          "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
          "bbox": [
            448.0,
            687.0,
            3023.0,
            738.0
          ],
          "confidence": 0.991033673286438
        },
        {
          "text": "New York, New York. USA are closed..",
          "bbox": [
            277.0,
            758.0,
            1129.0,
            804.0
          ],
          "confidence": 0.9706697463989258
        },
        {
          "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
          "bbox": [
            444.0,
            877.0,
            3027.0,
            934.0
          ],
          "confidence": 0.9889966249465942
        },
        {
          "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
          "bbox": [
            281.0,
            952.0,
            3023.0,
            998.0
          ],
          "confidence": 0.9837716221809387
        },
        {
          "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
          "bbox": [
            279.0,
            1018.0,
            3027.0,
            1069.0
          ],
          "confidence": 0.986255943775177
        },
        {
          "text": "Quarter shall end on the last day of the Term..",
          "bbox": [
            283.0,
            1089.0,
            1225.0,
            1131.0
          ],
          "confidence": 0.9884340763092041
        },
        {
          "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
          "bbox": [
            446.0,
            1204.0,
            3025.0,
            1259.0
          ],
          "confidence": 0.9859822988510132
        },
        {
          "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
          "bbox": [
            281.0,
            1281.0,
            3030.0,
            1325.0
          ],
          "confidence": 0.9892773032188416
        },
        {
          "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
          "bbox": [
            277.0,
            1343.0,
            3025.0,
            1394.0
          ],
          "confidence": 0.9878418445587158
        },
        {
          "text": "which the Term ends and end on the last day of the Term.",
          "bbox": [
            281.0,
            1411.0,
            1477.0,
            1458.0
          ],
          "confidence": 0.9887056350708008
        },
        {
          "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
          "bbox": [
            446.0,
            1531.0,
            3023.0,
            1584.0
          ],
          "confidence": 0.9936335682868958
        },
        {
          "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
          "bbox": [
            277.0,
            1604.0,
            2880.0,
            1656.0
          ],
          "confidence": 0.9896701574325562
        },
        {
          "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
          "bbox": [
            446.0,
            1725.0,
            3025.0,
            1776.0
          ],
          "confidence": 0.9879311919212341
        },
        {
          "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
          "bbox": [
            281.0,
            1800.0,
            1970.0,
            1844.0
          ],
          "confidence": 0.9974089860916138
        },
        {
          "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
          "bbox": [
            451.0,
            1921.0,
            2186.0,
            1964.0
          ],
          "confidence": 0.982360303401947
        },
        {
          "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
          "bbox": [
            444.0,
            2041.0,
            2126.0,
            2098.0
          ],
          "confidence": 0.9898555874824524
        },
        {
          "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
          "bbox": [
            450.0,
            2173.0,
            2132.0,
            2222.0
          ],
          "confidence": 0.9846742153167725
        },
        {
          "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
          "bbox": [
            448.0,
            2297.0,
            3027.0,
            2348.0
          ],
          "confidence": 0.9934711456298828
        },
        {
          "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
          "bbox": [
            279.0,
            2370.0,
            3025.0,
            2419.0
          ],
          "confidence": 0.9990534782409668
        },
        {
          "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
          "bbox": [
            279.0,
            2438.0,
            3029.0,
            2487.0
          ],
          "confidence": 0.9997351765632629
        },
        {
          "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
          "bbox": [
            277.0,
            2502.0,
            3027.0,
            2553.0
          ],
          "confidence": 0.9950071573257446
        },
        {
          "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
          "bbox": [
            277.0,
            2567.0,
            3027.0,
            2619.0
          ],
          "confidence": 0.9970062971115112
        },
        {
          "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
          "bbox": [
            279.0,
            2637.0,
            3029.0,
            2686.0
          ],
          "confidence": 0.9908316731452942
        },
        {
          "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
          "bbox": [
            277.0,
            2701.0,
            3029.0,
            2752.0
          ],
          "confidence": 0.9971660375595093
        },
        {
          "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
          "bbox": [
            281.0,
            2772.0,
            3025.0,
            2816.0
          ],
          "confidence": 0.998195230960846
        },
        {
          "text": "Agreement shall be considered Confidential Information of both Parties.",
          "bbox": [
            283.0,
            2838.0,
            1784.0,
            2882.0
          ],
          "confidence": 0.9954915642738342
        },
        {
          "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
          "bbox": [
            448.0,
            2955.0,
            2240.0,
            3008.0
          ],
          "confidence": 0.9914660453796387
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3143.0,
            1668.0,
            3181.0
          ],
          "confidence": 0.9956455826759338
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ],
          "confidence": 0.9981803894042969
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9841839671134949
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 8,
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Revenue/Profit Sharing_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Revenue/Profit Sharing_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
      "page_number": 8,
      "words": [
        {
          "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
          "bbox": [
            277.0,
            495.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9923841953277588
        },
        {
          "text": "to time.",
          "bbox": [
            276.0,
            566.0,
            433.0,
            612.0
          ],
          "confidence": 0.9964673519134521
        },
        {
          "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
          "bbox": [
            448.0,
            687.0,
            3023.0,
            738.0
          ],
          "confidence": 0.991033673286438
        },
        {
          "text": "New York, New York. USA are closed..",
          "bbox": [
            277.0,
            758.0,
            1129.0,
            804.0
          ],
          "confidence": 0.9706697463989258
        },
        {
          "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
          "bbox": [
            444.0,
            877.0,
            3027.0,
            934.0
          ],
          "confidence": 0.9889966249465942
        },
        {
          "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
          "bbox": [
            281.0,
            952.0,
            3023.0,
            998.0
          ],
          "confidence": 0.9837716221809387
        },
        {
          "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
          "bbox": [
            279.0,
            1018.0,
            3027.0,
            1069.0
          ],
          "confidence": 0.986255943775177
        },
        {
          "text": "Quarter shall end on the last day of the Term..",
          "bbox": [
            283.0,
            1089.0,
            1225.0,
            1131.0
          ],
          "confidence": 0.9884340763092041
        },
        {
          "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
          "bbox": [
            446.0,
            1204.0,
            3025.0,
            1259.0
          ],
          "confidence": 0.9859822988510132
        },
        {
          "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
          "bbox": [
            281.0,
            1281.0,
            3030.0,
            1325.0
          ],
          "confidence": 0.9892773032188416
        },
        {
          "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
          "bbox": [
            277.0,
            1343.0,
            3025.0,
            1394.0
          ],
          "confidence": 0.9878418445587158
        },
        {
          "text": "which the Term ends and end on the last day of the Term.",
          "bbox": [
            281.0,
            1411.0,
            1477.0,
            1458.0
          ],
          "confidence": 0.9887056350708008
        },
        {
          "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
          "bbox": [
            446.0,
            1531.0,
            3023.0,
            1584.0
          ],
          "confidence": 0.9936335682868958
        },
        {
          "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
          "bbox": [
            277.0,
            1604.0,
            2880.0,
            1656.0
          ],
          "confidence": 0.9896701574325562
        },
        {
          "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
          "bbox": [
            446.0,
            1725.0,
            3025.0,
            1776.0
          ],
          "confidence": 0.9879311919212341
        },
        {
          "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
          "bbox": [
            281.0,
            1800.0,
            1970.0,
            1844.0
          ],
          "confidence": 0.9974089860916138
        },
        {
          "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
          "bbox": [
            451.0,
            1921.0,
            2186.0,
            1964.0
          ],
          "confidence": 0.982360303401947
        },
        {
          "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
          "bbox": [
            444.0,
            2041.0,
            2126.0,
            2098.0
          ],
          "confidence": 0.9898555874824524
        },
        {
          "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
          "bbox": [
            450.0,
            2173.0,
            2132.0,
            2222.0
          ],
          "confidence": 0.9846742153167725
        },
        {
          "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
          "bbox": [
            448.0,
            2297.0,
            3027.0,
            2348.0
          ],
          "confidence": 0.9934711456298828
        },
        {
          "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
          "bbox": [
            279.0,
            2370.0,
            3025.0,
            2419.0
          ],
          "confidence": 0.9990534782409668
        },
        {
          "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
          "bbox": [
            279.0,
            2438.0,
            3029.0,
            2487.0
          ],
          "confidence": 0.9997351765632629
        },
        {
          "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
          "bbox": [
            277.0,
            2502.0,
            3027.0,
            2553.0
          ],
          "confidence": 0.9950071573257446
        },
        {
          "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
          "bbox": [
            277.0,
            2567.0,
            3027.0,
            2619.0
          ],
          "confidence": 0.9970062971115112
        },
        {
          "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
          "bbox": [
            279.0,
            2637.0,
            3029.0,
            2686.0
          ],
          "confidence": 0.9908316731452942
        },
        {
          "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
          "bbox": [
            277.0,
            2701.0,
            3029.0,
            2752.0
          ],
          "confidence": 0.9971660375595093
        },
        {
          "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
          "bbox": [
            281.0,
            2772.0,
            3025.0,
            2816.0
          ],
          "confidence": 0.998195230960846
        },
        {
          "text": "Agreement shall be considered Confidential Information of both Parties.",
          "bbox": [
            283.0,
            2838.0,
            1784.0,
            2882.0
          ],
          "confidence": 0.9954915642738342
        },
        {
          "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
          "bbox": [
            448.0,
            2955.0,
            2240.0,
            3008.0
          ],
          "confidence": 0.9914660453796387
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3143.0,
            1668.0,
            3181.0
          ],
          "confidence": 0.9956455826759338
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ],
          "confidence": 0.9981803894042969
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9841839671134949
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 8,
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Revenue/Profit Sharing_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Revenue/Profit Sharing_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
      "page_number": 8,
      "words": [
        {
          "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
          "bbox": [
            277.0,
            495.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9923841953277588
        },
        {
          "text": "to time.",
          "bbox": [
            276.0,
            566.0,
            433.0,
            612.0
          ],
          "confidence": 0.9964673519134521
        },
        {
          "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
          "bbox": [
            448.0,
            687.0,
            3023.0,
            738.0
          ],
          "confidence": 0.991033673286438
        },
        {
          "text": "New York, New York. USA are closed..",
          "bbox": [
            277.0,
            758.0,
            1129.0,
            804.0
          ],
          "confidence": 0.9706697463989258
        },
        {
          "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
          "bbox": [
            444.0,
            877.0,
            3027.0,
            934.0
          ],
          "confidence": 0.9889966249465942
        },
        {
          "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
          "bbox": [
            281.0,
            952.0,
            3023.0,
            998.0
          ],
          "confidence": 0.9837716221809387
        },
        {
          "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
          "bbox": [
            279.0,
            1018.0,
            3027.0,
            1069.0
          ],
          "confidence": 0.986255943775177
        },
        {
          "text": "Quarter shall end on the last day of the Term..",
          "bbox": [
            283.0,
            1089.0,
            1225.0,
            1131.0
          ],
          "confidence": 0.9884340763092041
        },
        {
          "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
          "bbox": [
            446.0,
            1204.0,
            3025.0,
            1259.0
          ],
          "confidence": 0.9859822988510132
        },
        {
          "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
          "bbox": [
            281.0,
            1281.0,
            3030.0,
            1325.0
          ],
          "confidence": 0.9892773032188416
        },
        {
          "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
          "bbox": [
            277.0,
            1343.0,
            3025.0,
            1394.0
          ],
          "confidence": 0.9878418445587158
        },
        {
          "text": "which the Term ends and end on the last day of the Term.",
          "bbox": [
            281.0,
            1411.0,
            1477.0,
            1458.0
          ],
          "confidence": 0.9887056350708008
        },
        {
          "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
          "bbox": [
            446.0,
            1531.0,
            3023.0,
            1584.0
          ],
          "confidence": 0.9936335682868958
        },
        {
          "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
          "bbox": [
            277.0,
            1604.0,
            2880.0,
            1656.0
          ],
          "confidence": 0.9896701574325562
        },
        {
          "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
          "bbox": [
            446.0,
            1725.0,
            3025.0,
            1776.0
          ],
          "confidence": 0.9879311919212341
        },
        {
          "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
          "bbox": [
            281.0,
            1800.0,
            1970.0,
            1844.0
          ],
          "confidence": 0.9974089860916138
        },
        {
          "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
          "bbox": [
            451.0,
            1921.0,
            2186.0,
            1964.0
          ],
          "confidence": 0.982360303401947
        },
        {
          "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
          "bbox": [
            444.0,
            2041.0,
            2126.0,
            2098.0
          ],
          "confidence": 0.9898555874824524
        },
        {
          "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
          "bbox": [
            450.0,
            2173.0,
            2132.0,
            2222.0
          ],
          "confidence": 0.9846742153167725
        },
        {
          "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
          "bbox": [
            448.0,
            2297.0,
            3027.0,
            2348.0
          ],
          "confidence": 0.9934711456298828
        },
        {
          "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
          "bbox": [
            279.0,
            2370.0,
            3025.0,
            2419.0
          ],
          "confidence": 0.9990534782409668
        },
        {
          "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
          "bbox": [
            279.0,
            2438.0,
            3029.0,
            2487.0
          ],
          "confidence": 0.9997351765632629
        },
        {
          "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
          "bbox": [
            277.0,
            2502.0,
            3027.0,
            2553.0
          ],
          "confidence": 0.9950071573257446
        },
        {
          "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
          "bbox": [
            277.0,
            2567.0,
            3027.0,
            2619.0
          ],
          "confidence": 0.9970062971115112
        },
        {
          "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
          "bbox": [
            279.0,
            2637.0,
            3029.0,
            2686.0
          ],
          "confidence": 0.9908316731452942
        },
        {
          "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
          "bbox": [
            277.0,
            2701.0,
            3029.0,
            2752.0
          ],
          "confidence": 0.9971660375595093
        },
        {
          "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
          "bbox": [
            281.0,
            2772.0,
            3025.0,
            2816.0
          ],
          "confidence": 0.998195230960846
        },
        {
          "text": "Agreement shall be considered Confidential Information of both Parties.",
          "bbox": [
            283.0,
            2838.0,
            1784.0,
            2882.0
          ],
          "confidence": 0.9954915642738342
        },
        {
          "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
          "bbox": [
            448.0,
            2955.0,
            2240.0,
            3008.0
          ],
          "confidence": 0.9914660453796387
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3143.0,
            1668.0,
            3181.0
          ],
          "confidence": 0.9956455826759338
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ],
          "confidence": 0.9981803894042969
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9841839671134949
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 8,
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
      "page_number": 8,
      "words": [
        {
          "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
          "bbox": [
            277.0,
            495.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9923841953277588
        },
        {
          "text": "to time.",
          "bbox": [
            276.0,
            566.0,
            433.0,
            612.0
          ],
          "confidence": 0.9964673519134521
        },
        {
          "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
          "bbox": [
            448.0,
            687.0,
            3023.0,
            738.0
          ],
          "confidence": 0.991033673286438
        },
        {
          "text": "New York, New York. USA are closed..",
          "bbox": [
            277.0,
            758.0,
            1129.0,
            804.0
          ],
          "confidence": 0.9706697463989258
        },
        {
          "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
          "bbox": [
            444.0,
            877.0,
            3027.0,
            934.0
          ],
          "confidence": 0.9889966249465942
        },
        {
          "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
          "bbox": [
            281.0,
            952.0,
            3023.0,
            998.0
          ],
          "confidence": 0.9837716221809387
        },
        {
          "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
          "bbox": [
            279.0,
            1018.0,
            3027.0,
            1069.0
          ],
          "confidence": 0.986255943775177
        },
        {
          "text": "Quarter shall end on the last day of the Term..",
          "bbox": [
            283.0,
            1089.0,
            1225.0,
            1131.0
          ],
          "confidence": 0.9884340763092041
        },
        {
          "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
          "bbox": [
            446.0,
            1204.0,
            3025.0,
            1259.0
          ],
          "confidence": 0.9859822988510132
        },
        {
          "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
          "bbox": [
            281.0,
            1281.0,
            3030.0,
            1325.0
          ],
          "confidence": 0.9892773032188416
        },
        {
          "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
          "bbox": [
            277.0,
            1343.0,
            3025.0,
            1394.0
          ],
          "confidence": 0.9878418445587158
        },
        {
          "text": "which the Term ends and end on the last day of the Term.",
          "bbox": [
            281.0,
            1411.0,
            1477.0,
            1458.0
          ],
          "confidence": 0.9887056350708008
        },
        {
          "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
          "bbox": [
            446.0,
            1531.0,
            3023.0,
            1584.0
          ],
          "confidence": 0.9936335682868958
        },
        {
          "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
          "bbox": [
            277.0,
            1604.0,
            2880.0,
            1656.0
          ],
          "confidence": 0.9896701574325562
        },
        {
          "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
          "bbox": [
            446.0,
            1725.0,
            3025.0,
            1776.0
          ],
          "confidence": 0.9879311919212341
        },
        {
          "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
          "bbox": [
            281.0,
            1800.0,
            1970.0,
            1844.0
          ],
          "confidence": 0.9974089860916138
        },
        {
          "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
          "bbox": [
            451.0,
            1921.0,
            2186.0,
            1964.0
          ],
          "confidence": 0.982360303401947
        },
        {
          "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
          "bbox": [
            444.0,
            2041.0,
            2126.0,
            2098.0
          ],
          "confidence": 0.9898555874824524
        },
        {
          "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
          "bbox": [
            450.0,
            2173.0,
            2132.0,
            2222.0
          ],
          "confidence": 0.9846742153167725
        },
        {
          "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
          "bbox": [
            448.0,
            2297.0,
            3027.0,
            2348.0
          ],
          "confidence": 0.9934711456298828
        },
        {
          "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
          "bbox": [
            279.0,
            2370.0,
            3025.0,
            2419.0
          ],
          "confidence": 0.9990534782409668
        },
        {
          "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
          "bbox": [
            279.0,
            2438.0,
            3029.0,
            2487.0
          ],
          "confidence": 0.9997351765632629
        },
        {
          "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
          "bbox": [
            277.0,
            2502.0,
            3027.0,
            2553.0
          ],
          "confidence": 0.9950071573257446
        },
        {
          "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
          "bbox": [
            277.0,
            2567.0,
            3027.0,
            2619.0
          ],
          "confidence": 0.9970062971115112
        },
        {
          "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
          "bbox": [
            279.0,
            2637.0,
            3029.0,
            2686.0
          ],
          "confidence": 0.9908316731452942
        },
        {
          "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
          "bbox": [
            277.0,
            2701.0,
            3029.0,
            2752.0
          ],
          "confidence": 0.9971660375595093
        },
        {
          "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
          "bbox": [
            281.0,
            2772.0,
            3025.0,
            2816.0
          ],
          "confidence": 0.998195230960846
        },
        {
          "text": "Agreement shall be considered Confidential Information of both Parties.",
          "bbox": [
            283.0,
            2838.0,
            1784.0,
            2882.0
          ],
          "confidence": 0.9954915642738342
        },
        {
          "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
          "bbox": [
            448.0,
            2955.0,
            2240.0,
            3008.0
          ],
          "confidence": 0.9914660453796387
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3143.0,
            1668.0,
            3181.0
          ],
          "confidence": 0.9956455826759338
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ],
          "confidence": 0.9981803894042969
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9841839671134949
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 8,
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_6",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "A Party shall have the right to terminate this Agreement before the end of the Term as follows:",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory.",
      "page_number": 8,
      "words": [
        {
          "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
          "bbox": [
            277.0,
            495.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9923841953277588
        },
        {
          "text": "to time.",
          "bbox": [
            276.0,
            566.0,
            433.0,
            612.0
          ],
          "confidence": 0.9964673519134521
        },
        {
          "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
          "bbox": [
            448.0,
            687.0,
            3023.0,
            738.0
          ],
          "confidence": 0.991033673286438
        },
        {
          "text": "New York, New York. USA are closed..",
          "bbox": [
            277.0,
            758.0,
            1129.0,
            804.0
          ],
          "confidence": 0.9706697463989258
        },
        {
          "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
          "bbox": [
            444.0,
            877.0,
            3027.0,
            934.0
          ],
          "confidence": 0.9889966249465942
        },
        {
          "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
          "bbox": [
            281.0,
            952.0,
            3023.0,
            998.0
          ],
          "confidence": 0.9837716221809387
        },
        {
          "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
          "bbox": [
            279.0,
            1018.0,
            3027.0,
            1069.0
          ],
          "confidence": 0.986255943775177
        },
        {
          "text": "Quarter shall end on the last day of the Term..",
          "bbox": [
            283.0,
            1089.0,
            1225.0,
            1131.0
          ],
          "confidence": 0.9884340763092041
        },
        {
          "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
          "bbox": [
            446.0,
            1204.0,
            3025.0,
            1259.0
          ],
          "confidence": 0.9859822988510132
        },
        {
          "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
          "bbox": [
            281.0,
            1281.0,
            3030.0,
            1325.0
          ],
          "confidence": 0.9892773032188416
        },
        {
          "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
          "bbox": [
            277.0,
            1343.0,
            3025.0,
            1394.0
          ],
          "confidence": 0.9878418445587158
        },
        {
          "text": "which the Term ends and end on the last day of the Term.",
          "bbox": [
            281.0,
            1411.0,
            1477.0,
            1458.0
          ],
          "confidence": 0.9887056350708008
        },
        {
          "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
          "bbox": [
            446.0,
            1531.0,
            3023.0,
            1584.0
          ],
          "confidence": 0.9936335682868958
        },
        {
          "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
          "bbox": [
            277.0,
            1604.0,
            2880.0,
            1656.0
          ],
          "confidence": 0.9896701574325562
        },
        {
          "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
          "bbox": [
            446.0,
            1725.0,
            3025.0,
            1776.0
          ],
          "confidence": 0.9879311919212341
        },
        {
          "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
          "bbox": [
            281.0,
            1800.0,
            1970.0,
            1844.0
          ],
          "confidence": 0.9974089860916138
        },
        {
          "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
          "bbox": [
            451.0,
            1921.0,
            2186.0,
            1964.0
          ],
          "confidence": 0.982360303401947
        },
        {
          "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
          "bbox": [
            444.0,
            2041.0,
            2126.0,
            2098.0
          ],
          "confidence": 0.9898555874824524
        },
        {
          "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
          "bbox": [
            450.0,
            2173.0,
            2132.0,
            2222.0
          ],
          "confidence": 0.9846742153167725
        },
        {
          "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
          "bbox": [
            448.0,
            2297.0,
            3027.0,
            2348.0
          ],
          "confidence": 0.9934711456298828
        },
        {
          "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
          "bbox": [
            279.0,
            2370.0,
            3025.0,
            2419.0
          ],
          "confidence": 0.9990534782409668
        },
        {
          "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
          "bbox": [
            279.0,
            2438.0,
            3029.0,
            2487.0
          ],
          "confidence": 0.9997351765632629
        },
        {
          "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
          "bbox": [
            277.0,
            2502.0,
            3027.0,
            2553.0
          ],
          "confidence": 0.9950071573257446
        },
        {
          "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
          "bbox": [
            277.0,
            2567.0,
            3027.0,
            2619.0
          ],
          "confidence": 0.9970062971115112
        },
        {
          "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
          "bbox": [
            279.0,
            2637.0,
            3029.0,
            2686.0
          ],
          "confidence": 0.9908316731452942
        },
        {
          "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
          "bbox": [
            277.0,
            2701.0,
            3029.0,
            2752.0
          ],
          "confidence": 0.9971660375595093
        },
        {
          "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
          "bbox": [
            281.0,
            2772.0,
            3025.0,
            2816.0
          ],
          "confidence": 0.998195230960846
        },
        {
          "text": "Agreement shall be considered Confidential Information of both Parties.",
          "bbox": [
            283.0,
            2838.0,
            1784.0,
            2882.0
          ],
          "confidence": 0.9954915642738342
        },
        {
          "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
          "bbox": [
            448.0,
            2955.0,
            2240.0,
            3008.0
          ],
          "confidence": 0.9914660453796387
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3143.0,
            1668.0,
            3181.0
          ],
          "confidence": 0.9956455826759338
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ],
          "confidence": 0.9981803894042969
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9841839671134949
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 8,
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "12.2.3 by Dova if the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the actual Details are less than the Quarterly Minimum Details;",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "12.2.3 by Dova if the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the actual Details are less than the Quarterly Minimum Details;",
      "page_number": 8,
      "words": [
        {
          "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
          "bbox": [
            277.0,
            495.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9923841953277588
        },
        {
          "text": "to time.",
          "bbox": [
            276.0,
            566.0,
            433.0,
            612.0
          ],
          "confidence": 0.9964673519134521
        },
        {
          "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
          "bbox": [
            448.0,
            687.0,
            3023.0,
            738.0
          ],
          "confidence": 0.991033673286438
        },
        {
          "text": "New York, New York. USA are closed..",
          "bbox": [
            277.0,
            758.0,
            1129.0,
            804.0
          ],
          "confidence": 0.9706697463989258
        },
        {
          "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
          "bbox": [
            444.0,
            877.0,
            3027.0,
            934.0
          ],
          "confidence": 0.9889966249465942
        },
        {
          "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
          "bbox": [
            281.0,
            952.0,
            3023.0,
            998.0
          ],
          "confidence": 0.9837716221809387
        },
        {
          "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
          "bbox": [
            279.0,
            1018.0,
            3027.0,
            1069.0
          ],
          "confidence": 0.986255943775177
        },
        {
          "text": "Quarter shall end on the last day of the Term..",
          "bbox": [
            283.0,
            1089.0,
            1225.0,
            1131.0
          ],
          "confidence": 0.9884340763092041
        },
        {
          "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
          "bbox": [
            446.0,
            1204.0,
            3025.0,
            1259.0
          ],
          "confidence": 0.9859822988510132
        },
        {
          "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
          "bbox": [
            281.0,
            1281.0,
            3030.0,
            1325.0
          ],
          "confidence": 0.9892773032188416
        },
        {
          "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
          "bbox": [
            277.0,
            1343.0,
            3025.0,
            1394.0
          ],
          "confidence": 0.9878418445587158
        },
        {
          "text": "which the Term ends and end on the last day of the Term.",
          "bbox": [
            281.0,
            1411.0,
            1477.0,
            1458.0
          ],
          "confidence": 0.9887056350708008
        },
        {
          "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
          "bbox": [
            446.0,
            1531.0,
            3023.0,
            1584.0
          ],
          "confidence": 0.9936335682868958
        },
        {
          "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
          "bbox": [
            277.0,
            1604.0,
            2880.0,
            1656.0
          ],
          "confidence": 0.9896701574325562
        },
        {
          "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
          "bbox": [
            446.0,
            1725.0,
            3025.0,
            1776.0
          ],
          "confidence": 0.9879311919212341
        },
        {
          "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
          "bbox": [
            281.0,
            1800.0,
            1970.0,
            1844.0
          ],
          "confidence": 0.9974089860916138
        },
        {
          "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
          "bbox": [
            451.0,
            1921.0,
            2186.0,
            1964.0
          ],
          "confidence": 0.982360303401947
        },
        {
          "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
          "bbox": [
            444.0,
            2041.0,
            2126.0,
            2098.0
          ],
          "confidence": 0.9898555874824524
        },
        {
          "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
          "bbox": [
            450.0,
            2173.0,
            2132.0,
            2222.0
          ],
          "confidence": 0.9846742153167725
        },
        {
          "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
          "bbox": [
            448.0,
            2297.0,
            3027.0,
            2348.0
          ],
          "confidence": 0.9934711456298828
        },
        {
          "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
          "bbox": [
            279.0,
            2370.0,
            3025.0,
            2419.0
          ],
          "confidence": 0.9990534782409668
        },
        {
          "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
          "bbox": [
            279.0,
            2438.0,
            3029.0,
            2487.0
          ],
          "confidence": 0.9997351765632629
        },
        {
          "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
          "bbox": [
            277.0,
            2502.0,
            3027.0,
            2553.0
          ],
          "confidence": 0.9950071573257446
        },
        {
          "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
          "bbox": [
            277.0,
            2567.0,
            3027.0,
            2619.0
          ],
          "confidence": 0.9970062971115112
        },
        {
          "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
          "bbox": [
            279.0,
            2637.0,
            3029.0,
            2686.0
          ],
          "confidence": 0.9908316731452942
        },
        {
          "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
          "bbox": [
            277.0,
            2701.0,
            3029.0,
            2752.0
          ],
          "confidence": 0.9971660375595093
        },
        {
          "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
          "bbox": [
            281.0,
            2772.0,
            3025.0,
            2816.0
          ],
          "confidence": 0.998195230960846
        },
        {
          "text": "Agreement shall be considered Confidential Information of both Parties.",
          "bbox": [
            283.0,
            2838.0,
            1784.0,
            2882.0
          ],
          "confidence": 0.9954915642738342
        },
        {
          "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
          "bbox": [
            448.0,
            2955.0,
            2240.0,
            3008.0
          ],
          "confidence": 0.9914660453796387
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3143.0,
            1668.0,
            3181.0
          ],
          "confidence": 0.9956455826759338
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ],
          "confidence": 0.9981803894042969
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9841839671134949
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 8,
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Minimum Commitment_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
      "page_number": 8,
      "words": [
        {
          "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
          "bbox": [
            277.0,
            495.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9923841953277588
        },
        {
          "text": "to time.",
          "bbox": [
            276.0,
            566.0,
            433.0,
            612.0
          ],
          "confidence": 0.9964673519134521
        },
        {
          "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
          "bbox": [
            448.0,
            687.0,
            3023.0,
            738.0
          ],
          "confidence": 0.991033673286438
        },
        {
          "text": "New York, New York. USA are closed..",
          "bbox": [
            277.0,
            758.0,
            1129.0,
            804.0
          ],
          "confidence": 0.9706697463989258
        },
        {
          "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
          "bbox": [
            444.0,
            877.0,
            3027.0,
            934.0
          ],
          "confidence": 0.9889966249465942
        },
        {
          "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
          "bbox": [
            281.0,
            952.0,
            3023.0,
            998.0
          ],
          "confidence": 0.9837716221809387
        },
        {
          "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
          "bbox": [
            279.0,
            1018.0,
            3027.0,
            1069.0
          ],
          "confidence": 0.986255943775177
        },
        {
          "text": "Quarter shall end on the last day of the Term..",
          "bbox": [
            283.0,
            1089.0,
            1225.0,
            1131.0
          ],
          "confidence": 0.9884340763092041
        },
        {
          "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
          "bbox": [
            446.0,
            1204.0,
            3025.0,
            1259.0
          ],
          "confidence": 0.9859822988510132
        },
        {
          "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
          "bbox": [
            281.0,
            1281.0,
            3030.0,
            1325.0
          ],
          "confidence": 0.9892773032188416
        },
        {
          "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
          "bbox": [
            277.0,
            1343.0,
            3025.0,
            1394.0
          ],
          "confidence": 0.9878418445587158
        },
        {
          "text": "which the Term ends and end on the last day of the Term.",
          "bbox": [
            281.0,
            1411.0,
            1477.0,
            1458.0
          ],
          "confidence": 0.9887056350708008
        },
        {
          "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
          "bbox": [
            446.0,
            1531.0,
            3023.0,
            1584.0
          ],
          "confidence": 0.9936335682868958
        },
        {
          "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
          "bbox": [
            277.0,
            1604.0,
            2880.0,
            1656.0
          ],
          "confidence": 0.9896701574325562
        },
        {
          "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
          "bbox": [
            446.0,
            1725.0,
            3025.0,
            1776.0
          ],
          "confidence": 0.9879311919212341
        },
        {
          "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
          "bbox": [
            281.0,
            1800.0,
            1970.0,
            1844.0
          ],
          "confidence": 0.9974089860916138
        },
        {
          "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
          "bbox": [
            451.0,
            1921.0,
            2186.0,
            1964.0
          ],
          "confidence": 0.982360303401947
        },
        {
          "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
          "bbox": [
            444.0,
            2041.0,
            2126.0,
            2098.0
          ],
          "confidence": 0.9898555874824524
        },
        {
          "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
          "bbox": [
            450.0,
            2173.0,
            2132.0,
            2222.0
          ],
          "confidence": 0.9846742153167725
        },
        {
          "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
          "bbox": [
            448.0,
            2297.0,
            3027.0,
            2348.0
          ],
          "confidence": 0.9934711456298828
        },
        {
          "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
          "bbox": [
            279.0,
            2370.0,
            3025.0,
            2419.0
          ],
          "confidence": 0.9990534782409668
        },
        {
          "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
          "bbox": [
            279.0,
            2438.0,
            3029.0,
            2487.0
          ],
          "confidence": 0.9997351765632629
        },
        {
          "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
          "bbox": [
            277.0,
            2502.0,
            3027.0,
            2553.0
          ],
          "confidence": 0.9950071573257446
        },
        {
          "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
          "bbox": [
            277.0,
            2567.0,
            3027.0,
            2619.0
          ],
          "confidence": 0.9970062971115112
        },
        {
          "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
          "bbox": [
            279.0,
            2637.0,
            3029.0,
            2686.0
          ],
          "confidence": 0.9908316731452942
        },
        {
          "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
          "bbox": [
            277.0,
            2701.0,
            3029.0,
            2752.0
          ],
          "confidence": 0.9971660375595093
        },
        {
          "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
          "bbox": [
            281.0,
            2772.0,
            3025.0,
            2816.0
          ],
          "confidence": 0.998195230960846
        },
        {
          "text": "Agreement shall be considered Confidential Information of both Parties.",
          "bbox": [
            283.0,
            2838.0,
            1784.0,
            2882.0
          ],
          "confidence": 0.9954915642738342
        },
        {
          "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
          "bbox": [
            448.0,
            2955.0,
            2240.0,
            3008.0
          ],
          "confidence": 0.9914660453796387
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3143.0,
            1668.0,
            3181.0
          ],
          "confidence": 0.9956455826759338
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ],
          "confidence": 0.9981803894042969
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9841839671134949
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 8,
          "bbox": [
            1030.0,
            3452.0,
            2278.0,
            3483.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Ip Ownership Assignment_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "As between the Parties, Dova shall own all right, title and interest in and to any Product Materials (and all content contained therein) and any Product Labeling (and all content contained therein), including applicable copyrights and trademarks (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling), and to the extent Valeant (or any of its Affiliates) obtains or otherwise has a claim to any of the foregoing, Valeant hereby assigns (and shall cause any applicable Affiliate to assign) all of its right, title and interest in and to such Product Materials (and content) and Product Labeling (and content) (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling) to Dova and Valeant agrees to (and shall cause its applicable Affiliate to) execute all documents and take all actions as are reasonably requested by Dova to vest title to such Product Materials (and content) and Product Labeling (and content) in Dova (or its designated Affiliate).",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Ip Ownership Assignment_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "As between the Parties, Dova shall own all right, title and interest in and to any Product Materials (and all content contained therein) and any Product Labeling (and all content contained therein), including applicable copyrights and trademarks (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling), and to the extent Valeant (or any of its Affiliates) obtains or otherwise has a claim to any of the foregoing, Valeant hereby assigns (and shall cause any applicable Affiliate to assign) all of its right, title and interest in and to such Product Materials (and content) and Product Labeling (and content) (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling) to Dova and Valeant agrees to (and shall cause its applicable Affiliate to) execute all documents and take all actions as are reasonably requested by Dova to vest title to such Product Materials (and content) and Product Labeling (and content) in Dova (or its designated Affiliate).",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Ip Ownership Assignment_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "The ownership, and all goodwill from the use, of any Dova Trademarks and Copyrights shall at all times vest in and inure to the benefit of Dova, and Valeant shall assign, and hereby does assign, any rights it may have in the foregoing to Dova.",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Ip Ownership Assignment_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "The ownership, and all goodwill from the use, of any Dova Trademarks and Copyrights shall at all times vest in and inure to the benefit of Dova, and Valeant shall assign, and hereby does assign, any rights it may have in the foregoing to Dova.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Ip Ownership Assignment_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Valeant agrees to assign, and hereby does assign, to Dova (and shall cause its Affiliates and its and their respective employees and other representatives to assign to Dova) any and all right, title and interest that Valeant (or any such Affiliates, employees or other representatives) may have in or to any Invention.",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Ip Ownership Assignment_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Valeant agrees to assign, and hereby does assign, to Dova (and shall cause its Affiliates and its and their respective employees and other representatives to assign to Dova) any and all right, title and interest that Valeant (or any such Affiliates, employees or other representatives) may have in or to any Invention.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2800.0,
            283.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9779579043388367
        },
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ],
          "confidence": 0.9996495842933655
        },
        {
          "text": "by and between",
          "bbox": [
            1477.0,
            872.0,
            1834.0,
            915.0
          ],
          "confidence": 0.9997774958610535
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ],
          "confidence": 0.9989398121833801
        },
        {
          "text": "and",
          "bbox": [
            1605.0,
            1278.0,
            1701.0,
            1331.0
          ],
          "confidence": 0.9980132579803467
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ],
          "confidence": 0.9993768334388733
        },
        {
          "text": "September 26, 2018",
          "bbox": [
            1419.0,
            1637.0,
            1883.0,
            1692.0
          ],
          "confidence": 0.9950999021530151
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ],
          "confidence": 0.989909827709198
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ],
          "confidence": 0.994059681892395
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9876725673675537
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ],
          "confidence": 0.9780283570289612
        },
        {
          "text": "Page",
          "bbox": [
            2776.0,
            688.0,
            2901.0,
            750.0
          ],
          "confidence": 0.9999327659606934
        },
        {
          "text": "1",
          "bbox": [
            2864.0,
            917.0,
            2902.0,
            968.0
          ],
          "confidence": 0.9995635151863098
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ],
          "confidence": 0.9859031438827515
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ],
          "confidence": 0.9988932013511658
        },
        {
          "text": "8",
          "bbox": [
            2864.0,
            1029.0,
            2902.0,
            1082.0
          ],
          "confidence": 0.9996312856674194
        },
        {
          "text": "2.1 Engagement; Grant of Rights.",
          "bbox": [
            254.0,
            1142.0,
            1035.0,
            1193.0
          ],
          "confidence": 0.9930101633071899
        },
        {
          "text": "8",
          "bbox": [
            2866.0,
            1142.0,
            2904.0,
            1193.0
          ],
          "confidence": 0.9996554851531982
        },
        {
          "text": "2.2 Retention of Rights.",
          "bbox": [
            255.0,
            1255.0,
            803.0,
            1305.0
          ],
          "confidence": 0.9952546954154968
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1254.0,
            2902.0,
            1305.0
          ],
          "confidence": 0.99913090467453
        },
        {
          "text": "2.3 Non-Competition; Non-Solicitation.",
          "bbox": [
            255.0,
            1369.0,
            1155.0,
            1416.0
          ],
          "confidence": 0.9856934547424316
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1365.0,
            2902.0,
            1418.0
          ],
          "confidence": 0.9992173910140991
        },
        {
          "text": "2.4 Dova Trademarks and Copyrights.",
          "bbox": [
            256.0,
            1482.0,
            1135.0,
            1528.0
          ],
          "confidence": 0.9905837178230286
        },
        {
          "text": "10",
          "bbox": [
            2837.0,
            1476.0,
            2904.0,
            1531.0
          ],
          "confidence": 0.9995734095573425
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ],
          "confidence": 0.9954172968864441
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1592.0,
            2900.0,
            1641.0
          ],
          "confidence": 0.9997044801712036
        },
        {
          "text": "3.1 Formation of the JSC.",
          "bbox": [
            256.0,
            1707.0,
            839.0,
            1751.0
          ],
          "confidence": 0.992499589920044
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1705.0,
            2900.0,
            1754.0
          ],
          "confidence": 0.9998102188110352
        },
        {
          "text": "3.2 Meetings and Minutes..",
          "bbox": [
            255.0,
            1818.0,
            877.0,
            1866.0
          ],
          "confidence": 0.9774132370948792
        },
        {
          "text": "11",
          "bbox": [
            2840.0,
            1813.0,
            2902.0,
            1868.0
          ],
          "confidence": 0.9997932314872742
        },
        {
          "text": "3.3 Purpose of the JSC",
          "bbox": [
            256.0,
            1933.0,
            790.0,
            1975.0
          ],
          "confidence": 0.9881646633148193
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1928.0,
            2900.0,
            1977.0
          ],
          "confidence": 0.9997947812080383
        },
        {
          "text": "3.4 Decision Making..",
          "bbox": [
            252.0,
            2035.0,
            751.0,
            2094.0
          ],
          "confidence": 0.954731285572052
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2037.0,
            2904.0,
            2090.0
          ],
          "confidence": 0.9999567270278931
        },
        {
          "text": "3.5 Marketing Sub-Committee.",
          "bbox": [
            255.0,
            2154.0,
            972.0,
            2204.0
          ],
          "confidence": 0.9678689241409302
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2151.0,
            2902.0,
            2204.0
          ],
          "confidence": 0.9999614953994751
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ],
          "confidence": 0.999039351940155
        },
        {
          "text": "14",
          "bbox": [
            2838.0,
            2262.0,
            2904.0,
            2315.0
          ],
          "confidence": 0.9999129176139832
        },
        {
          "text": "4.1 Valeant Activities.",
          "bbox": [
            254.0,
            2379.0,
            756.0,
            2427.0
          ],
          "confidence": 0.9994301199913025
        },
        {
          "text": "14",
          "bbox": [
            2835.0,
            2376.0,
            2904.0,
            2429.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "4.2 Detailing.",
          "bbox": [
            251.0,
            2485.0,
            561.0,
            2544.0
          ],
          "confidence": 0.947688102722168
        },
        {
          "text": "15",
          "bbox": [
            2837.0,
            2485.0,
            2904.0,
            2542.0
          ],
          "confidence": 0.9998620748519897
        },
        {
          "text": "4.3 Compliance with Applicable Law.",
          "bbox": [
            254.0,
            2604.0,
            1097.0,
            2652.0
          ],
          "confidence": 0.999403178691864
        },
        {
          "text": "17",
          "bbox": [
            2837.0,
            2598.0,
            2904.0,
            2653.0
          ],
          "confidence": 0.9998419284820557
        },
        {
          "text": "4.4 Field Force Personnel Training; Product Materials..",
          "bbox": [
            256.0,
            2717.0,
            1515.0,
            2761.0
          ],
          "confidence": 0.9813730120658875
        },
        {
          "text": "19",
          "bbox": [
            2835.0,
            2712.0,
            2904.0,
            2765.0
          ],
          "confidence": 0.9997812509536743
        },
        {
          "text": "4.5 Provisions Related to Field Force Personnel",
          "bbox": [
            254.0,
            2829.0,
            1367.0,
            2874.0
          ],
          "confidence": 0.999675989151001
        },
        {
          "text": "21",
          "bbox": [
            2835.0,
            2825.0,
            2900.0,
            2878.0
          ],
          "confidence": 0.9999203681945801
        },
        {
          "text": "4.6 Responsibility for Valeant Activity Costs and Expenses..",
          "bbox": [
            256.0,
            2940.0,
            1628.0,
            2988.0
          ],
          "confidence": 0.983078122138977
        },
        {
          "text": "22",
          "bbox": [
            2835.0,
            2937.0,
            2902.0,
            2990.0
          ],
          "confidence": 0.9998236894607544
        },
        {
          "text": "4.7 Data Sharing.",
          "bbox": [
            252.0,
            3048.0,
            653.0,
            3105.0
          ],
          "confidence": 0.975680947303772
        },
        {
          "text": "22",
          "bbox": [
            2838.0,
            3052.0,
            2900.0,
            3099.0
          ],
          "confidence": 0.9997785091400146
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ],
          "confidence": 0.9930562376976013
        },
        {
          "text": "MATTERS",
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ],
          "confidence": 0.999487042427063
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3231.0,
            2902.0,
            3286.0
          ],
          "confidence": 0.999907374382019
        },
        {
          "text": "5.1 Dova Responsibility",
          "bbox": [
            256.0,
            3349.0,
            814.0,
            3395.0
          ],
          "confidence": 0.9984672665596008
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3342.0,
            2902.0,
            3397.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "5.2 Valeant Involvement.",
          "bbox": [
            256.0,
            3463.0,
            827.0,
            3503.0
          ],
          "confidence": 0.9985610842704773
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3456.0,
            2902.0,
            3508.0
          ],
          "confidence": 0.9999406337738037
        },
        {
          "text": "23",
          "bbox": [
            2834.0,
            3564.0,
            2904.0,
            3624.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "5.3 Inspections.",
          "bbox": [
            256.0,
            3576.0,
            609.0,
            3620.0
          ],
          "confidence": 0.9983316659927368
        },
        {
          "text": "5.4 Pharmacovigilance.",
          "bbox": [
            254.0,
            3684.0,
            783.0,
            3732.0
          ],
          "confidence": 0.9932737946510315
        },
        {
          "text": "24",
          "bbox": [
            2837.0,
            3680.0,
            2904.0,
            3733.0
          ],
          "confidence": 0.9999386668205261
        },
        {
          "text": "5.5 Unsolicited Requests for Medical Information.",
          "bbox": [
            254.0,
            3797.0,
            1414.0,
            3843.0
          ],
          "confidence": 0.9851503372192383
        },
        {
          "text": "24",
          "bbox": [
            2835.0,
            3792.0,
            2904.0,
            3845.0
          ],
          "confidence": 0.9999282956123352
        },
        {
          "text": "5.6 Recalls and Market Withdrawals",
          "bbox": [
            257.0,
            3911.0,
            1115.0,
            3953.0
          ],
          "confidence": 0.9952821135520935
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            3903.0,
            2904.0,
            3958.0
          ],
          "confidence": 0.9998209476470947
        },
        {
          "text": "5.7 Certain Reporting Responsibilities",
          "bbox": [
            256.0,
            4026.0,
            1153.0,
            4068.0
          ],
          "confidence": 0.9995793700218201
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4017.0,
            2904.0,
            4069.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "5.8 Booking of Sales Revenues.",
          "bbox": [
            254.0,
            4132.0,
            993.0,
            4181.0
          ],
          "confidence": 0.9986859560012817
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4128.0,
            2904.0,
            4183.0
          ],
          "confidence": 0.9998403787612915
        },
        {
          "text": "5.9 Returns.",
          "bbox": [
            253.0,
            4243.0,
            539.0,
            4295.0
          ],
          "confidence": 0.9989113807678223
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4239.0,
            2904.0,
            4296.0
          ],
          "confidence": 0.9997888803482056
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9973026514053345
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ]
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "page": 1,
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ]
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "page": 1,
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ]
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "page": 1,
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ]
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "page": 1,
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ]
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "page": 1,
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ]
        },
        {
          "text": "MATTERS",
          "page": 1,
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Valeant shall have the non-exclusive right to use the Dova Trademarks and Copyrights solely on Product Materials in order to perform the Valeant Activities and solely in accordance with the terms and conditions of this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2800.0,
            283.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9779579043388367
        },
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ],
          "confidence": 0.9996495842933655
        },
        {
          "text": "by and between",
          "bbox": [
            1477.0,
            872.0,
            1834.0,
            915.0
          ],
          "confidence": 0.9997774958610535
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ],
          "confidence": 0.9989398121833801
        },
        {
          "text": "and",
          "bbox": [
            1605.0,
            1278.0,
            1701.0,
            1331.0
          ],
          "confidence": 0.9980132579803467
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ],
          "confidence": 0.9993768334388733
        },
        {
          "text": "September 26, 2018",
          "bbox": [
            1419.0,
            1637.0,
            1883.0,
            1692.0
          ],
          "confidence": 0.9950999021530151
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ],
          "confidence": 0.989909827709198
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ],
          "confidence": 0.994059681892395
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9876725673675537
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Valeant shall have the non-exclusive right to use the Dova Trademarks and Copyrights solely on Product Materials in order to perform the Valeant Activities and solely in accordance with the terms and conditions of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ],
          "confidence": 0.9780283570289612
        },
        {
          "text": "Page",
          "bbox": [
            2776.0,
            688.0,
            2901.0,
            750.0
          ],
          "confidence": 0.9999327659606934
        },
        {
          "text": "1",
          "bbox": [
            2864.0,
            917.0,
            2902.0,
            968.0
          ],
          "confidence": 0.9995635151863098
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ],
          "confidence": 0.9859031438827515
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ],
          "confidence": 0.9988932013511658
        },
        {
          "text": "8",
          "bbox": [
            2864.0,
            1029.0,
            2902.0,
            1082.0
          ],
          "confidence": 0.9996312856674194
        },
        {
          "text": "2.1 Engagement; Grant of Rights.",
          "bbox": [
            254.0,
            1142.0,
            1035.0,
            1193.0
          ],
          "confidence": 0.9930101633071899
        },
        {
          "text": "8",
          "bbox": [
            2866.0,
            1142.0,
            2904.0,
            1193.0
          ],
          "confidence": 0.9996554851531982
        },
        {
          "text": "2.2 Retention of Rights.",
          "bbox": [
            255.0,
            1255.0,
            803.0,
            1305.0
          ],
          "confidence": 0.9952546954154968
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1254.0,
            2902.0,
            1305.0
          ],
          "confidence": 0.99913090467453
        },
        {
          "text": "2.3 Non-Competition; Non-Solicitation.",
          "bbox": [
            255.0,
            1369.0,
            1155.0,
            1416.0
          ],
          "confidence": 0.9856934547424316
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1365.0,
            2902.0,
            1418.0
          ],
          "confidence": 0.9992173910140991
        },
        {
          "text": "2.4 Dova Trademarks and Copyrights.",
          "bbox": [
            256.0,
            1482.0,
            1135.0,
            1528.0
          ],
          "confidence": 0.9905837178230286
        },
        {
          "text": "10",
          "bbox": [
            2837.0,
            1476.0,
            2904.0,
            1531.0
          ],
          "confidence": 0.9995734095573425
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ],
          "confidence": 0.9954172968864441
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1592.0,
            2900.0,
            1641.0
          ],
          "confidence": 0.9997044801712036
        },
        {
          "text": "3.1 Formation of the JSC.",
          "bbox": [
            256.0,
            1707.0,
            839.0,
            1751.0
          ],
          "confidence": 0.992499589920044
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1705.0,
            2900.0,
            1754.0
          ],
          "confidence": 0.9998102188110352
        },
        {
          "text": "3.2 Meetings and Minutes..",
          "bbox": [
            255.0,
            1818.0,
            877.0,
            1866.0
          ],
          "confidence": 0.9774132370948792
        },
        {
          "text": "11",
          "bbox": [
            2840.0,
            1813.0,
            2902.0,
            1868.0
          ],
          "confidence": 0.9997932314872742
        },
        {
          "text": "3.3 Purpose of the JSC",
          "bbox": [
            256.0,
            1933.0,
            790.0,
            1975.0
          ],
          "confidence": 0.9881646633148193
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1928.0,
            2900.0,
            1977.0
          ],
          "confidence": 0.9997947812080383
        },
        {
          "text": "3.4 Decision Making..",
          "bbox": [
            252.0,
            2035.0,
            751.0,
            2094.0
          ],
          "confidence": 0.954731285572052
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2037.0,
            2904.0,
            2090.0
          ],
          "confidence": 0.9999567270278931
        },
        {
          "text": "3.5 Marketing Sub-Committee.",
          "bbox": [
            255.0,
            2154.0,
            972.0,
            2204.0
          ],
          "confidence": 0.9678689241409302
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2151.0,
            2902.0,
            2204.0
          ],
          "confidence": 0.9999614953994751
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ],
          "confidence": 0.999039351940155
        },
        {
          "text": "14",
          "bbox": [
            2838.0,
            2262.0,
            2904.0,
            2315.0
          ],
          "confidence": 0.9999129176139832
        },
        {
          "text": "4.1 Valeant Activities.",
          "bbox": [
            254.0,
            2379.0,
            756.0,
            2427.0
          ],
          "confidence": 0.9994301199913025
        },
        {
          "text": "14",
          "bbox": [
            2835.0,
            2376.0,
            2904.0,
            2429.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "4.2 Detailing.",
          "bbox": [
            251.0,
            2485.0,
            561.0,
            2544.0
          ],
          "confidence": 0.947688102722168
        },
        {
          "text": "15",
          "bbox": [
            2837.0,
            2485.0,
            2904.0,
            2542.0
          ],
          "confidence": 0.9998620748519897
        },
        {
          "text": "4.3 Compliance with Applicable Law.",
          "bbox": [
            254.0,
            2604.0,
            1097.0,
            2652.0
          ],
          "confidence": 0.999403178691864
        },
        {
          "text": "17",
          "bbox": [
            2837.0,
            2598.0,
            2904.0,
            2653.0
          ],
          "confidence": 0.9998419284820557
        },
        {
          "text": "4.4 Field Force Personnel Training; Product Materials..",
          "bbox": [
            256.0,
            2717.0,
            1515.0,
            2761.0
          ],
          "confidence": 0.9813730120658875
        },
        {
          "text": "19",
          "bbox": [
            2835.0,
            2712.0,
            2904.0,
            2765.0
          ],
          "confidence": 0.9997812509536743
        },
        {
          "text": "4.5 Provisions Related to Field Force Personnel",
          "bbox": [
            254.0,
            2829.0,
            1367.0,
            2874.0
          ],
          "confidence": 0.999675989151001
        },
        {
          "text": "21",
          "bbox": [
            2835.0,
            2825.0,
            2900.0,
            2878.0
          ],
          "confidence": 0.9999203681945801
        },
        {
          "text": "4.6 Responsibility for Valeant Activity Costs and Expenses..",
          "bbox": [
            256.0,
            2940.0,
            1628.0,
            2988.0
          ],
          "confidence": 0.983078122138977
        },
        {
          "text": "22",
          "bbox": [
            2835.0,
            2937.0,
            2902.0,
            2990.0
          ],
          "confidence": 0.9998236894607544
        },
        {
          "text": "4.7 Data Sharing.",
          "bbox": [
            252.0,
            3048.0,
            653.0,
            3105.0
          ],
          "confidence": 0.975680947303772
        },
        {
          "text": "22",
          "bbox": [
            2838.0,
            3052.0,
            2900.0,
            3099.0
          ],
          "confidence": 0.9997785091400146
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ],
          "confidence": 0.9930562376976013
        },
        {
          "text": "MATTERS",
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ],
          "confidence": 0.999487042427063
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3231.0,
            2902.0,
            3286.0
          ],
          "confidence": 0.999907374382019
        },
        {
          "text": "5.1 Dova Responsibility",
          "bbox": [
            256.0,
            3349.0,
            814.0,
            3395.0
          ],
          "confidence": 0.9984672665596008
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3342.0,
            2902.0,
            3397.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "5.2 Valeant Involvement.",
          "bbox": [
            256.0,
            3463.0,
            827.0,
            3503.0
          ],
          "confidence": 0.9985610842704773
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3456.0,
            2902.0,
            3508.0
          ],
          "confidence": 0.9999406337738037
        },
        {
          "text": "23",
          "bbox": [
            2834.0,
            3564.0,
            2904.0,
            3624.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "5.3 Inspections.",
          "bbox": [
            256.0,
            3576.0,
            609.0,
            3620.0
          ],
          "confidence": 0.9983316659927368
        },
        {
          "text": "5.4 Pharmacovigilance.",
          "bbox": [
            254.0,
            3684.0,
            783.0,
            3732.0
          ],
          "confidence": 0.9932737946510315
        },
        {
          "text": "24",
          "bbox": [
            2837.0,
            3680.0,
            2904.0,
            3733.0
          ],
          "confidence": 0.9999386668205261
        },
        {
          "text": "5.5 Unsolicited Requests for Medical Information.",
          "bbox": [
            254.0,
            3797.0,
            1414.0,
            3843.0
          ],
          "confidence": 0.9851503372192383
        },
        {
          "text": "24",
          "bbox": [
            2835.0,
            3792.0,
            2904.0,
            3845.0
          ],
          "confidence": 0.9999282956123352
        },
        {
          "text": "5.6 Recalls and Market Withdrawals",
          "bbox": [
            257.0,
            3911.0,
            1115.0,
            3953.0
          ],
          "confidence": 0.9952821135520935
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            3903.0,
            2904.0,
            3958.0
          ],
          "confidence": 0.9998209476470947
        },
        {
          "text": "5.7 Certain Reporting Responsibilities",
          "bbox": [
            256.0,
            4026.0,
            1153.0,
            4068.0
          ],
          "confidence": 0.9995793700218201
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4017.0,
            2904.0,
            4069.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "5.8 Booking of Sales Revenues.",
          "bbox": [
            254.0,
            4132.0,
            993.0,
            4181.0
          ],
          "confidence": 0.9986859560012817
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4128.0,
            2904.0,
            4183.0
          ],
          "confidence": 0.9998403787612915
        },
        {
          "text": "5.9 Returns.",
          "bbox": [
            253.0,
            4243.0,
            539.0,
            4295.0
          ],
          "confidence": 0.9989113807678223
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4239.0,
            2904.0,
            4296.0
          ],
          "confidence": 0.9997888803482056
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9973026514053345
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ]
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "page": 1,
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ]
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "page": 1,
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ]
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "page": 1,
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ]
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "page": 1,
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ]
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "page": 1,
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ]
        },
        {
          "text": "MATTERS",
          "page": 1,
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__License Grant_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__License Grant_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Non-Transferable License_1",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Except to Affiliates of Valeant, Valeant's rights and obligations under this Section 2.1 are non-transferable, non-assignable, and non-delegable.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ],
          "confidence": 0.9780283570289612
        },
        {
          "text": "Page",
          "bbox": [
            2776.0,
            688.0,
            2901.0,
            750.0
          ],
          "confidence": 0.9999327659606934
        },
        {
          "text": "1",
          "bbox": [
            2864.0,
            917.0,
            2902.0,
            968.0
          ],
          "confidence": 0.9995635151863098
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ],
          "confidence": 0.9859031438827515
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ],
          "confidence": 0.9988932013511658
        },
        {
          "text": "8",
          "bbox": [
            2864.0,
            1029.0,
            2902.0,
            1082.0
          ],
          "confidence": 0.9996312856674194
        },
        {
          "text": "2.1 Engagement; Grant of Rights.",
          "bbox": [
            254.0,
            1142.0,
            1035.0,
            1193.0
          ],
          "confidence": 0.9930101633071899
        },
        {
          "text": "8",
          "bbox": [
            2866.0,
            1142.0,
            2904.0,
            1193.0
          ],
          "confidence": 0.9996554851531982
        },
        {
          "text": "2.2 Retention of Rights.",
          "bbox": [
            255.0,
            1255.0,
            803.0,
            1305.0
          ],
          "confidence": 0.9952546954154968
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1254.0,
            2902.0,
            1305.0
          ],
          "confidence": 0.99913090467453
        },
        {
          "text": "2.3 Non-Competition; Non-Solicitation.",
          "bbox": [
            255.0,
            1369.0,
            1155.0,
            1416.0
          ],
          "confidence": 0.9856934547424316
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1365.0,
            2902.0,
            1418.0
          ],
          "confidence": 0.9992173910140991
        },
        {
          "text": "2.4 Dova Trademarks and Copyrights.",
          "bbox": [
            256.0,
            1482.0,
            1135.0,
            1528.0
          ],
          "confidence": 0.9905837178230286
        },
        {
          "text": "10",
          "bbox": [
            2837.0,
            1476.0,
            2904.0,
            1531.0
          ],
          "confidence": 0.9995734095573425
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ],
          "confidence": 0.9954172968864441
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1592.0,
            2900.0,
            1641.0
          ],
          "confidence": 0.9997044801712036
        },
        {
          "text": "3.1 Formation of the JSC.",
          "bbox": [
            256.0,
            1707.0,
            839.0,
            1751.0
          ],
          "confidence": 0.992499589920044
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1705.0,
            2900.0,
            1754.0
          ],
          "confidence": 0.9998102188110352
        },
        {
          "text": "3.2 Meetings and Minutes..",
          "bbox": [
            255.0,
            1818.0,
            877.0,
            1866.0
          ],
          "confidence": 0.9774132370948792
        },
        {
          "text": "11",
          "bbox": [
            2840.0,
            1813.0,
            2902.0,
            1868.0
          ],
          "confidence": 0.9997932314872742
        },
        {
          "text": "3.3 Purpose of the JSC",
          "bbox": [
            256.0,
            1933.0,
            790.0,
            1975.0
          ],
          "confidence": 0.9881646633148193
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1928.0,
            2900.0,
            1977.0
          ],
          "confidence": 0.9997947812080383
        },
        {
          "text": "3.4 Decision Making..",
          "bbox": [
            252.0,
            2035.0,
            751.0,
            2094.0
          ],
          "confidence": 0.954731285572052
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2037.0,
            2904.0,
            2090.0
          ],
          "confidence": 0.9999567270278931
        },
        {
          "text": "3.5 Marketing Sub-Committee.",
          "bbox": [
            255.0,
            2154.0,
            972.0,
            2204.0
          ],
          "confidence": 0.9678689241409302
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2151.0,
            2902.0,
            2204.0
          ],
          "confidence": 0.9999614953994751
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ],
          "confidence": 0.999039351940155
        },
        {
          "text": "14",
          "bbox": [
            2838.0,
            2262.0,
            2904.0,
            2315.0
          ],
          "confidence": 0.9999129176139832
        },
        {
          "text": "4.1 Valeant Activities.",
          "bbox": [
            254.0,
            2379.0,
            756.0,
            2427.0
          ],
          "confidence": 0.9994301199913025
        },
        {
          "text": "14",
          "bbox": [
            2835.0,
            2376.0,
            2904.0,
            2429.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "4.2 Detailing.",
          "bbox": [
            251.0,
            2485.0,
            561.0,
            2544.0
          ],
          "confidence": 0.947688102722168
        },
        {
          "text": "15",
          "bbox": [
            2837.0,
            2485.0,
            2904.0,
            2542.0
          ],
          "confidence": 0.9998620748519897
        },
        {
          "text": "4.3 Compliance with Applicable Law.",
          "bbox": [
            254.0,
            2604.0,
            1097.0,
            2652.0
          ],
          "confidence": 0.999403178691864
        },
        {
          "text": "17",
          "bbox": [
            2837.0,
            2598.0,
            2904.0,
            2653.0
          ],
          "confidence": 0.9998419284820557
        },
        {
          "text": "4.4 Field Force Personnel Training; Product Materials..",
          "bbox": [
            256.0,
            2717.0,
            1515.0,
            2761.0
          ],
          "confidence": 0.9813730120658875
        },
        {
          "text": "19",
          "bbox": [
            2835.0,
            2712.0,
            2904.0,
            2765.0
          ],
          "confidence": 0.9997812509536743
        },
        {
          "text": "4.5 Provisions Related to Field Force Personnel",
          "bbox": [
            254.0,
            2829.0,
            1367.0,
            2874.0
          ],
          "confidence": 0.999675989151001
        },
        {
          "text": "21",
          "bbox": [
            2835.0,
            2825.0,
            2900.0,
            2878.0
          ],
          "confidence": 0.9999203681945801
        },
        {
          "text": "4.6 Responsibility for Valeant Activity Costs and Expenses..",
          "bbox": [
            256.0,
            2940.0,
            1628.0,
            2988.0
          ],
          "confidence": 0.983078122138977
        },
        {
          "text": "22",
          "bbox": [
            2835.0,
            2937.0,
            2902.0,
            2990.0
          ],
          "confidence": 0.9998236894607544
        },
        {
          "text": "4.7 Data Sharing.",
          "bbox": [
            252.0,
            3048.0,
            653.0,
            3105.0
          ],
          "confidence": 0.975680947303772
        },
        {
          "text": "22",
          "bbox": [
            2838.0,
            3052.0,
            2900.0,
            3099.0
          ],
          "confidence": 0.9997785091400146
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ],
          "confidence": 0.9930562376976013
        },
        {
          "text": "MATTERS",
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ],
          "confidence": 0.999487042427063
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3231.0,
            2902.0,
            3286.0
          ],
          "confidence": 0.999907374382019
        },
        {
          "text": "5.1 Dova Responsibility",
          "bbox": [
            256.0,
            3349.0,
            814.0,
            3395.0
          ],
          "confidence": 0.9984672665596008
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3342.0,
            2902.0,
            3397.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "5.2 Valeant Involvement.",
          "bbox": [
            256.0,
            3463.0,
            827.0,
            3503.0
          ],
          "confidence": 0.9985610842704773
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3456.0,
            2902.0,
            3508.0
          ],
          "confidence": 0.9999406337738037
        },
        {
          "text": "23",
          "bbox": [
            2834.0,
            3564.0,
            2904.0,
            3624.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "5.3 Inspections.",
          "bbox": [
            256.0,
            3576.0,
            609.0,
            3620.0
          ],
          "confidence": 0.9983316659927368
        },
        {
          "text": "5.4 Pharmacovigilance.",
          "bbox": [
            254.0,
            3684.0,
            783.0,
            3732.0
          ],
          "confidence": 0.9932737946510315
        },
        {
          "text": "24",
          "bbox": [
            2837.0,
            3680.0,
            2904.0,
            3733.0
          ],
          "confidence": 0.9999386668205261
        },
        {
          "text": "5.5 Unsolicited Requests for Medical Information.",
          "bbox": [
            254.0,
            3797.0,
            1414.0,
            3843.0
          ],
          "confidence": 0.9851503372192383
        },
        {
          "text": "24",
          "bbox": [
            2835.0,
            3792.0,
            2904.0,
            3845.0
          ],
          "confidence": 0.9999282956123352
        },
        {
          "text": "5.6 Recalls and Market Withdrawals",
          "bbox": [
            257.0,
            3911.0,
            1115.0,
            3953.0
          ],
          "confidence": 0.9952821135520935
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            3903.0,
            2904.0,
            3958.0
          ],
          "confidence": 0.9998209476470947
        },
        {
          "text": "5.7 Certain Reporting Responsibilities",
          "bbox": [
            256.0,
            4026.0,
            1153.0,
            4068.0
          ],
          "confidence": 0.9995793700218201
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4017.0,
            2904.0,
            4069.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "5.8 Booking of Sales Revenues.",
          "bbox": [
            254.0,
            4132.0,
            993.0,
            4181.0
          ],
          "confidence": 0.9986859560012817
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4128.0,
            2904.0,
            4183.0
          ],
          "confidence": 0.9998403787612915
        },
        {
          "text": "5.9 Returns.",
          "bbox": [
            253.0,
            4243.0,
            539.0,
            4295.0
          ],
          "confidence": 0.9989113807678223
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4239.0,
            2904.0,
            4296.0
          ],
          "confidence": 0.9997888803482056
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9973026514053345
        }
      ],
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ]
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "page": 1,
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ]
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "page": 1,
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ]
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "page": 1,
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ]
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "page": 1,
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ]
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "page": 1,
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ]
        },
        {
          "text": "MATTERS",
          "page": 1,
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Non-Transferable License_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Non-Transferable License_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Affiliate License-Licensee_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Affiliate License-Licensee_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Dova shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through a certified public accounting firm or other auditor selected by Dova and reasonably acceptable to Valeant and upon execution of a confidentiality agreement reasonably satisfactory to Valeant in form and substance, to inspect and audit the applicable records and books maintained by Valeant relating to the Valeant Activities for purposes of verifying Valeant's compliance with the terms of this Agreement, provided that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Dova shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant compliance problems relating to Valeant's obligations hereunder or in response to any inquiry, inspection, investigation or other requirements of a Government Authority in the Territory relating to the Valeant Activities.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Dova shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through a certified public accounting firm or other auditor selected by Dova and reasonably acceptable to Valeant and upon execution of a confidentiality agreement reasonably satisfactory to Valeant in form and substance, to inspect and audit the applicable records and books maintained by Valeant relating to the Valeant Activities for purposes of verifying Valeant's compliance with the terms of this Agreement, provided that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Dova shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant compliance problems relating to Valeant's obligations hereunder or in response to any inquiry, inspection, investigation or other requirements of a Government Authority in the Territory relating to the Valeant Activities.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_9_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Valeant shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed under-reporting or underpayment for that audited period in excess of [***] of the amounts properly determined, in which case, Dova shall reimburse Valeant for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.",
      "page_number": 9,
      "words": [
        {
          "text": "1.18 Designated Product' shall mean a specific pharmaceutical product marketed by Valeant which is agreed to in",
          "bbox": [
            446.0,
            493.0,
            3023.0,
            545.0
          ],
          "confidence": 0.9922788739204407
        },
        {
          "text": "writing by the Parties on or prior to the Effective Date..",
          "bbox": [
            283.0,
            566.0,
            1414.0,
            614.0
          ],
          "confidence": 0.9786798357963562
        },
        {
          "text": "1.19 \"Detail(s)'' shall mean a Product presentation during a face-to-face sales call between a Target Professional and a",
          "bbox": [
            448.0,
            689.0,
            3027.0,
            738.0
          ],
          "confidence": 0.982406497001648
        },
        {
          "text": "Sales Representative, during which a presentation of the Product's attributes, benefits, prescribing information and safety",
          "bbox": [
            279.0,
            758.0,
            3023.0,
            810.0
          ],
          "confidence": 0.9963512420654297
        },
        {
          "text": "exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.",
          "bbox": [
            281.0,
            894.0,
            2786.0,
            943.0
          ],
          "confidence": 0.9951563477516174
        },
        {
          "text": "1.20 *Detail Report' shall have the meaning set forth in Section 4.2.2.",
          "bbox": [
            450.0,
            1014.0,
            1945.0,
            1064.0
          ],
          "confidence": 0.9864112734794617
        },
        {
          "text": "1.21 'Dispute\"' shall have the meaning set forth in Section 13.6.1..",
          "bbox": [
            448.0,
            1138.0,
            1831.0,
            1190.0
          ],
          "confidence": 0.9735655784606934
        },
        {
          "text": "1.22 \"Dollar\" or \"$' shall mean United States dollar..",
          "bbox": [
            449.0,
            1264.0,
            1555.0,
            1312.0
          ],
          "confidence": 0.9746863842010498
        },
        {
          "text": "1.23 \"Dova Trademarks and Copyrights\"' shall mean the logos, trade dress, slogans, domain names and housemarks of",
          "bbox": [
            450.0,
            1394.0,
            3030.0,
            1444.0
          ],
          "confidence": 0.9848853349685669
        },
        {
          "text": "Dova or any of its Affiliates as may appear on any Product Materials or Product Labeling, in each case, as may be updated from",
          "bbox": [
            277.0,
            1464.0,
            3027.0,
            1519.0
          ],
          "confidence": 0.9942975640296936
        },
        {
          "text": "time to time by Dova..",
          "bbox": [
            279.0,
            1531.0,
            731.0,
            1579.0
          ],
          "confidence": 0.9773948788642883
        },
        {
          "text": "1.24 'Dova's Third Party Data Source\" shall mean [***] or such other data source as selected by Dova and with",
          "bbox": [
            444.0,
            1646.0,
            3025.0,
            1703.0
          ],
          "confidence": 0.9831746220588684
        },
        {
          "text": "which Dova enters into an agreement, at its cost.",
          "bbox": [
            281.0,
            1723.0,
            1294.0,
            1773.0
          ],
          "confidence": 0.987755298614502
        },
        {
          "text": "1.25 \"Effective Date' shall have the meaning set forth in the preamble to this Agreement.",
          "bbox": [
            448.0,
            1844.0,
            2336.0,
            1897.0
          ],
          "confidence": 0.9881223440170288
        },
        {
          "text": "1.26 \"FDA\" shall mean the United States Food and Drug Administration or any successor agency performing comparable",
          "bbox": [
            448.0,
            1970.0,
            3025.0,
            2023.0
          ],
          "confidence": 0.9781140089035034
        },
        {
          "text": "functions.",
          "bbox": [
            275.0,
            2037.0,
            475.0,
            2093.0
          ],
          "confidence": 0.9968258142471313
        },
        {
          "text": "1.27 'Field\" shall mean the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled",
          "bbox": [
            444.0,
            2160.0,
            3029.0,
            2217.0
          ],
          "confidence": 0.9887498021125793
        },
        {
          "text": "to undergo a procedure and any and all additional indications for which the Product is approved in the Territory.",
          "bbox": [
            279.0,
            2233.0,
            2619.0,
            2288.0
          ],
          "confidence": 0.9928398728370667
        },
        {
          "text": "1.28 \"Field Force Personnel' shall mean collectively, the Sales Representatives, the members of the institutional account",
          "bbox": [
            448.0,
            2355.0,
            3029.0,
            2407.0
          ],
          "confidence": 0.9825577139854431
        },
        {
          "text": "management team described in Section 4.1.5, if any, that are engaged in Detailing the Product and any other employees of Valeant",
          "bbox": [
            274.0,
            2425.0,
            3031.0,
            2482.0
          ],
          "confidence": 0.9971492290496826
        },
        {
          "text": "engaged in the Valeant Activities..",
          "bbox": [
            281.0,
            2494.0,
            963.0,
            2544.0
          ],
          "confidence": 0.9812881350517273
        },
        {
          "text": "1.29 \"GAAP\" shall mean United States generally accepted accounting principles.",
          "bbox": [
            446.0,
            2613.0,
            2144.0,
            2672.0
          ],
          "confidence": 0.9943995475769043
        },
        {
          "text": "1.30 \"Governmental Authority\" shall mean any court, agency, authority, department, regulatory body or other",
          "bbox": [
            444.0,
            2739.0,
            3029.0,
            2800.0
          ],
          "confidence": 0.9906880855560303
        },
        {
          "text": "instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political",
          "bbox": [
            279.0,
            2814.0,
            3027.0,
            2865.0
          ],
          "confidence": 0.99421226978302
        },
        {
          "text": "subdivision of any such government or any supranational organization of which any such country is a member, which has competent.",
          "bbox": [
            283.0,
            2885.0,
            3027.0,
            2929.0
          ],
          "confidence": 0.9955881834030151
        },
        {
          "text": "and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this",
          "bbox": [
            283.0,
            2951.0,
            3025.0,
            2995.0
          ],
          "confidence": 0.9951909184455872
        },
        {
          "text": "Agreement.",
          "bbox": [
            281.0,
            3019.0,
            520.0,
            3063.0
          ],
          "confidence": 0.9976062774658203
        },
        {
          "text": "4",
          "bbox": [
            1642.0,
            3200.0,
            1666.0,
            3225.0
          ],
          "confidence": 0.8676274418830872
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            3507.0,
            2275.0,
            3532.0
          ],
          "confidence": 0.9973365664482117
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9947719573974609
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 9,
          "bbox": [
            1031.0,
            3507.0,
            2275.0,
            3532.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_10_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Valeant shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed under-reporting or underpayment for that audited period in excess of [***] of the amounts properly determined, in which case, Dova shall reimburse Valeant for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.",
      "page_number": 10,
      "words": [
        {
          "text": "1.31 \"Gross to Net Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the net",
          "bbox": [
            446.0,
            497.0,
            3029.0,
            548.0
          ],
          "confidence": 0.9874702095985413
        },
        {
          "text": "sales of the SKU of the Product in the Territory for an applicable period (based on the gross-to-net discounts for all sales of such",
          "bbox": [
            279.0,
            570.0,
            3027.0,
            619.0
          ],
          "confidence": 0.9992752075195312
        },
        {
          "text": "SKU of the Product (i.e., sales attributable to the Specialty, as well as all other sales of such SKU of the Product), and (ii) the",
          "bbox": [
            277.0,
            634.0,
            3025.0,
            685.0
          ],
          "confidence": 0.989626944065094
        },
        {
          "text": "denominator of which is gross sales of such SKU of the Product in the Territory for an applicable period, in each case, as",
          "bbox": [
            275.0,
            700.0,
            3029.0,
            757.0
          ],
          "confidence": 0.9913815855979919
        },
        {
          "text": "determined in accordance with Dova's revenue recognition policies, which is in accordance with GAAP (on a consistent basis), for",
          "bbox": [
            283.0,
            773.0,
            3025.0,
            817.0
          ],
          "confidence": 0.9897457361221313
        },
        {
          "text": "quarterly financial reporting purposes, as reported in Dova's quarterly filings with the U.S. Securities Exchange Commission.",
          "bbox": [
            283.0,
            839.0,
            2884.0,
            888.0
          ],
          "confidence": 0.9902921915054321
        },
        {
          "text": "1.32 \"Indemnified Party'' shall have the meaning set forth in Section 11.3..",
          "bbox": [
            450.0,
            958.0,
            2017.0,
            1007.0
          ],
          "confidence": 0.965660572052002
        },
        {
          "text": "1.33 \"Indemnifying Party' shall have the meaning set forth in Section 11.3..",
          "bbox": [
            448.0,
            1082.0,
            2046.0,
            1135.0
          ],
          "confidence": 0.9826773405075073
        },
        {
          "text": "1.34 \"Intellectual Property\" shall have the meaning set forth in Section 8.1.2",
          "bbox": [
            446.0,
            1208.0,
            2101.0,
            1263.0
          ],
          "confidence": 0.9879571795463562
        },
        {
          "text": "1.35 \"Intermediary\" shall mean any wholesaler or distributor who sells Product to Retail Pharmacies and Non-Retail",
          "bbox": [
            450.0,
            1338.0,
            3029.0,
            1387.0
          ],
          "confidence": 0.9892066717147827
        },
        {
          "text": "Institutions, but not patients, and with which Dova (or its Affiliates) has entered into an agreement or otherwise has arrangements.",
          "bbox": [
            279.0,
            1407.0,
            2983.0,
            1458.0
          ],
          "confidence": 0.9925985336303711
        },
        {
          "text": "1.36 \"Inventions\"' shall have the meaning set forth in Section 8.1.2.",
          "bbox": [
            450.0,
            1529.0,
            1867.0,
            1579.0
          ],
          "confidence": 0.9816356301307678
        },
        {
          "text": "1.37 \"JSC\" shall have the meaning set forth in Section 3.1.",
          "bbox": [
            450.0,
            1656.0,
            1680.0,
            1705.0
          ],
          "confidence": 0.979685366153717
        },
        {
          "text": "1.38 \"Know-How\"' shall mean information, whether or not in written form, including biological, chemical, pharmacological,",
          "bbox": [
            446.0,
            1782.0,
            3023.0,
            1833.0
          ],
          "confidence": 0.9908992648124695
        },
        {
          "text": "toxicological, medical or clinical, analytical, quality, manufacturing, research, or sales and marketing information, including",
          "bbox": [
            279.0,
            1851.0,
            3027.0,
            1906.0
          ],
          "confidence": 0.9901236295700073
        },
        {
          "text": "processes, methods, procedures, techniques, plans, programs and data.",
          "bbox": [
            281.0,
            1922.0,
            1785.0,
            1972.0
          ],
          "confidence": 0.9997182488441467
        },
        {
          "text": "1.39 \"Losses\" shall mean any and all amounts paid or payable to Third Parties with respect to a Claim (including any and.",
          "bbox": [
            446.0,
            2039.0,
            3025.0,
            2094.0
          ],
          "confidence": 0.9901546835899353
        },
        {
          "text": "all losses, damages, obligations, liabilities, fines, fees, penalties, awards, judgments, interest), together with all documented out-of-",
          "bbox": [
            283.0,
            2114.0,
            3023.0,
            2164.0
          ],
          "confidence": 0.9965105056762695
        },
        {
          "text": "pocket costs and expenses, including attorney's fees, reasonably incurred..",
          "bbox": [
            279.0,
            2178.0,
            1831.0,
            2229.0
          ],
          "confidence": 0.9926494359970093
        },
        {
          "text": "1.40 *Net Sales\"' shall mean, for an applicable period, the aggregate amount, without duplication, equal to the Specialty",
          "bbox": [
            444.0,
            2299.0,
            3021.0,
            2355.0
          ],
          "confidence": 0.989584743976593
        },
        {
          "text": "Pharmacy Net Sales for each SKU, the Retail Net Sales for each SKU, if any, and the Non-Retail Net Sales for each SKU.",
          "bbox": [
            281.0,
            2372.0,
            2893.0,
            2421.0
          ],
          "confidence": 0.9925589561462402
        },
        {
          "text": "1.41 *Non-Retail Institution' shall mean any institution (other than the Specialty Pharmacies, Retail Pharmacies and",
          "bbox": [
            446.0,
            2492.0,
            3029.0,
            2544.0
          ],
          "confidence": 0.9886279106140137
        },
        {
          "text": "Intermediaries) to which Dova (or its Affiliates or its Intermediaries) sells and/or ships units of Product during the Term, which shall",
          "bbox": [
            279.0,
            2566.0,
            3027.0,
            2613.0
          ],
          "confidence": 0.9940993189811707
        },
        {
          "text": "include group purchasing organizations (GPOs), hospitals, clinics, long term care facilities and any outlets that are a member of an",
          "bbox": [
            277.0,
            2631.0,
            3027.0,
            2684.0
          ],
          "confidence": 0.9924531579017639
        },
        {
          "text": "Integrated Delivery Network (IDN), and with which Dova or its Affiliates do not have data agreements which enables Dova to",
          "bbox": [
            281.0,
            2703.0,
            3025.0,
            2746.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "track shipments of Product from such institution to patients based on the Target Professional prescribing such Product.",
          "bbox": [
            283.0,
            2768.0,
            2755.0,
            2812.0
          ],
          "confidence": 0.9929245114326477
        },
        {
          "text": "1.42 \"Non-Retail Net Sales'' shall mean, for each SKU of the Product:.",
          "bbox": [
            449.0,
            2887.0,
            1979.0,
            2933.0
          ],
          "confidence": 0.9764129519462585
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "bbox": [
            370.0,
            3331.0,
            2938.0,
            3370.0
          ],
          "confidence": 0.994901180267334
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            3384.0,
            2276.0,
            3410.0
          ],
          "confidence": 0.9962199926376343
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9899002313613892
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 10,
          "bbox": [
            370.0,
            3331.0,
            2938.0,
            3370.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 10,
          "bbox": [
            1031.0,
            3384.0,
            2276.0,
            3410.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Valeant shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through certified public accounting firm or other auditor selected by Valeant and reasonably acceptable to Dova and upon execution of a confidentiality agreement reasonably satisfactory to Dova in form and substance, to inspect and audit the applicable records and books maintained by Dova for purposes of verifying Dova's payment obligations within this Agreement, including the applicable records and books of account maintained by Dova, or any Affiliate, as applicable, with respect to Net Sales in order to confirm the accuracy and completeness of such records and books of account and all payments hereunder; provided, however, that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Valeant shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant problems relating to Dova's payment obligations hereunder.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Valeant shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through certified public accounting firm or other auditor selected by Valeant and reasonably acceptable to Dova and upon execution of a confidentiality agreement reasonably satisfactory to Dova in form and substance, to inspect and audit the applicable records and books maintained by Dova for purposes of verifying Dova's payment obligations within this Agreement, including the applicable records and books of account maintained by Dova, or any Affiliate, as applicable, with respect to Net Sales in order to confirm the accuracy and completeness of such records and books of account and all payments hereunder; provided, however, that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Valeant shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant problems relating to Dova's payment obligations hereunder.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_9",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Where necessary, on reasonable request, Dova's audit rights shall include interviewing Sales Representatives and other employees of Valeant.",
      "page_number": 9,
      "words": [
        {
          "text": "1.18 Designated Product' shall mean a specific pharmaceutical product marketed by Valeant which is agreed to in",
          "bbox": [
            446.0,
            493.0,
            3023.0,
            545.0
          ],
          "confidence": 0.9922788739204407
        },
        {
          "text": "writing by the Parties on or prior to the Effective Date..",
          "bbox": [
            283.0,
            566.0,
            1414.0,
            614.0
          ],
          "confidence": 0.9786798357963562
        },
        {
          "text": "1.19 \"Detail(s)'' shall mean a Product presentation during a face-to-face sales call between a Target Professional and a",
          "bbox": [
            448.0,
            689.0,
            3027.0,
            738.0
          ],
          "confidence": 0.982406497001648
        },
        {
          "text": "Sales Representative, during which a presentation of the Product's attributes, benefits, prescribing information and safety",
          "bbox": [
            279.0,
            758.0,
            3023.0,
            810.0
          ],
          "confidence": 0.9963512420654297
        },
        {
          "text": "exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.",
          "bbox": [
            281.0,
            894.0,
            2786.0,
            943.0
          ],
          "confidence": 0.9951563477516174
        },
        {
          "text": "1.20 *Detail Report' shall have the meaning set forth in Section 4.2.2.",
          "bbox": [
            450.0,
            1014.0,
            1945.0,
            1064.0
          ],
          "confidence": 0.9864112734794617
        },
        {
          "text": "1.21 'Dispute\"' shall have the meaning set forth in Section 13.6.1..",
          "bbox": [
            448.0,
            1138.0,
            1831.0,
            1190.0
          ],
          "confidence": 0.9735655784606934
        },
        {
          "text": "1.22 \"Dollar\" or \"$' shall mean United States dollar..",
          "bbox": [
            449.0,
            1264.0,
            1555.0,
            1312.0
          ],
          "confidence": 0.9746863842010498
        },
        {
          "text": "1.23 \"Dova Trademarks and Copyrights\"' shall mean the logos, trade dress, slogans, domain names and housemarks of",
          "bbox": [
            450.0,
            1394.0,
            3030.0,
            1444.0
          ],
          "confidence": 0.9848853349685669
        },
        {
          "text": "Dova or any of its Affiliates as may appear on any Product Materials or Product Labeling, in each case, as may be updated from",
          "bbox": [
            277.0,
            1464.0,
            3027.0,
            1519.0
          ],
          "confidence": 0.9942975640296936
        },
        {
          "text": "time to time by Dova..",
          "bbox": [
            279.0,
            1531.0,
            731.0,
            1579.0
          ],
          "confidence": 0.9773948788642883
        },
        {
          "text": "1.24 'Dova's Third Party Data Source\" shall mean [***] or such other data source as selected by Dova and with",
          "bbox": [
            444.0,
            1646.0,
            3025.0,
            1703.0
          ],
          "confidence": 0.9831746220588684
        },
        {
          "text": "which Dova enters into an agreement, at its cost.",
          "bbox": [
            281.0,
            1723.0,
            1294.0,
            1773.0
          ],
          "confidence": 0.987755298614502
        },
        {
          "text": "1.25 \"Effective Date' shall have the meaning set forth in the preamble to this Agreement.",
          "bbox": [
            448.0,
            1844.0,
            2336.0,
            1897.0
          ],
          "confidence": 0.9881223440170288
        },
        {
          "text": "1.26 \"FDA\" shall mean the United States Food and Drug Administration or any successor agency performing comparable",
          "bbox": [
            448.0,
            1970.0,
            3025.0,
            2023.0
          ],
          "confidence": 0.9781140089035034
        },
        {
          "text": "functions.",
          "bbox": [
            275.0,
            2037.0,
            475.0,
            2093.0
          ],
          "confidence": 0.9968258142471313
        },
        {
          "text": "1.27 'Field\" shall mean the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled",
          "bbox": [
            444.0,
            2160.0,
            3029.0,
            2217.0
          ],
          "confidence": 0.9887498021125793
        },
        {
          "text": "to undergo a procedure and any and all additional indications for which the Product is approved in the Territory.",
          "bbox": [
            279.0,
            2233.0,
            2619.0,
            2288.0
          ],
          "confidence": 0.9928398728370667
        },
        {
          "text": "1.28 \"Field Force Personnel' shall mean collectively, the Sales Representatives, the members of the institutional account",
          "bbox": [
            448.0,
            2355.0,
            3029.0,
            2407.0
          ],
          "confidence": 0.9825577139854431
        },
        {
          "text": "management team described in Section 4.1.5, if any, that are engaged in Detailing the Product and any other employees of Valeant",
          "bbox": [
            274.0,
            2425.0,
            3031.0,
            2482.0
          ],
          "confidence": 0.9971492290496826
        },
        {
          "text": "engaged in the Valeant Activities..",
          "bbox": [
            281.0,
            2494.0,
            963.0,
            2544.0
          ],
          "confidence": 0.9812881350517273
        },
        {
          "text": "1.29 \"GAAP\" shall mean United States generally accepted accounting principles.",
          "bbox": [
            446.0,
            2613.0,
            2144.0,
            2672.0
          ],
          "confidence": 0.9943995475769043
        },
        {
          "text": "1.30 \"Governmental Authority\" shall mean any court, agency, authority, department, regulatory body or other",
          "bbox": [
            444.0,
            2739.0,
            3029.0,
            2800.0
          ],
          "confidence": 0.9906880855560303
        },
        {
          "text": "instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political",
          "bbox": [
            279.0,
            2814.0,
            3027.0,
            2865.0
          ],
          "confidence": 0.99421226978302
        },
        {
          "text": "subdivision of any such government or any supranational organization of which any such country is a member, which has competent.",
          "bbox": [
            283.0,
            2885.0,
            3027.0,
            2929.0
          ],
          "confidence": 0.9955881834030151
        },
        {
          "text": "and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this",
          "bbox": [
            283.0,
            2951.0,
            3025.0,
            2995.0
          ],
          "confidence": 0.9951909184455872
        },
        {
          "text": "Agreement.",
          "bbox": [
            281.0,
            3019.0,
            520.0,
            3063.0
          ],
          "confidence": 0.9976062774658203
        },
        {
          "text": "4",
          "bbox": [
            1642.0,
            3200.0,
            1666.0,
            3225.0
          ],
          "confidence": 0.8676274418830872
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            3507.0,
            2275.0,
            3532.0
          ],
          "confidence": 0.9973365664482117
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9947719573974609
        }
      ],
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 9,
          "bbox": [
            1031.0,
            3507.0,
            2275.0,
            3532.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_9_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Dova shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed over- payment for that audited period in excess of [***] of the amounts properly determined, in which case, Valeant shall reimburse Dova for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.",
      "page_number": 9,
      "words": [
        {
          "text": "1.18 Designated Product' shall mean a specific pharmaceutical product marketed by Valeant which is agreed to in",
          "bbox": [
            446.0,
            493.0,
            3023.0,
            545.0
          ],
          "confidence": 0.9922788739204407
        },
        {
          "text": "writing by the Parties on or prior to the Effective Date..",
          "bbox": [
            283.0,
            566.0,
            1414.0,
            614.0
          ],
          "confidence": 0.9786798357963562
        },
        {
          "text": "1.19 \"Detail(s)'' shall mean a Product presentation during a face-to-face sales call between a Target Professional and a",
          "bbox": [
            448.0,
            689.0,
            3027.0,
            738.0
          ],
          "confidence": 0.982406497001648
        },
        {
          "text": "Sales Representative, during which a presentation of the Product's attributes, benefits, prescribing information and safety",
          "bbox": [
            279.0,
            758.0,
            3023.0,
            810.0
          ],
          "confidence": 0.9963512420654297
        },
        {
          "text": "exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.",
          "bbox": [
            281.0,
            894.0,
            2786.0,
            943.0
          ],
          "confidence": 0.9951563477516174
        },
        {
          "text": "1.20 *Detail Report' shall have the meaning set forth in Section 4.2.2.",
          "bbox": [
            450.0,
            1014.0,
            1945.0,
            1064.0
          ],
          "confidence": 0.9864112734794617
        },
        {
          "text": "1.21 'Dispute\"' shall have the meaning set forth in Section 13.6.1..",
          "bbox": [
            448.0,
            1138.0,
            1831.0,
            1190.0
          ],
          "confidence": 0.9735655784606934
        },
        {
          "text": "1.22 \"Dollar\" or \"$' shall mean United States dollar..",
          "bbox": [
            449.0,
            1264.0,
            1555.0,
            1312.0
          ],
          "confidence": 0.9746863842010498
        },
        {
          "text": "1.23 \"Dova Trademarks and Copyrights\"' shall mean the logos, trade dress, slogans, domain names and housemarks of",
          "bbox": [
            450.0,
            1394.0,
            3030.0,
            1444.0
          ],
          "confidence": 0.9848853349685669
        },
        {
          "text": "Dova or any of its Affiliates as may appear on any Product Materials or Product Labeling, in each case, as may be updated from",
          "bbox": [
            277.0,
            1464.0,
            3027.0,
            1519.0
          ],
          "confidence": 0.9942975640296936
        },
        {
          "text": "time to time by Dova..",
          "bbox": [
            279.0,
            1531.0,
            731.0,
            1579.0
          ],
          "confidence": 0.9773948788642883
        },
        {
          "text": "1.24 'Dova's Third Party Data Source\" shall mean [***] or such other data source as selected by Dova and with",
          "bbox": [
            444.0,
            1646.0,
            3025.0,
            1703.0
          ],
          "confidence": 0.9831746220588684
        },
        {
          "text": "which Dova enters into an agreement, at its cost.",
          "bbox": [
            281.0,
            1723.0,
            1294.0,
            1773.0
          ],
          "confidence": 0.987755298614502
        },
        {
          "text": "1.25 \"Effective Date' shall have the meaning set forth in the preamble to this Agreement.",
          "bbox": [
            448.0,
            1844.0,
            2336.0,
            1897.0
          ],
          "confidence": 0.9881223440170288
        },
        {
          "text": "1.26 \"FDA\" shall mean the United States Food and Drug Administration or any successor agency performing comparable",
          "bbox": [
            448.0,
            1970.0,
            3025.0,
            2023.0
          ],
          "confidence": 0.9781140089035034
        },
        {
          "text": "functions.",
          "bbox": [
            275.0,
            2037.0,
            475.0,
            2093.0
          ],
          "confidence": 0.9968258142471313
        },
        {
          "text": "1.27 'Field\" shall mean the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled",
          "bbox": [
            444.0,
            2160.0,
            3029.0,
            2217.0
          ],
          "confidence": 0.9887498021125793
        },
        {
          "text": "to undergo a procedure and any and all additional indications for which the Product is approved in the Territory.",
          "bbox": [
            279.0,
            2233.0,
            2619.0,
            2288.0
          ],
          "confidence": 0.9928398728370667
        },
        {
          "text": "1.28 \"Field Force Personnel' shall mean collectively, the Sales Representatives, the members of the institutional account",
          "bbox": [
            448.0,
            2355.0,
            3029.0,
            2407.0
          ],
          "confidence": 0.9825577139854431
        },
        {
          "text": "management team described in Section 4.1.5, if any, that are engaged in Detailing the Product and any other employees of Valeant",
          "bbox": [
            274.0,
            2425.0,
            3031.0,
            2482.0
          ],
          "confidence": 0.9971492290496826
        },
        {
          "text": "engaged in the Valeant Activities..",
          "bbox": [
            281.0,
            2494.0,
            963.0,
            2544.0
          ],
          "confidence": 0.9812881350517273
        },
        {
          "text": "1.29 \"GAAP\" shall mean United States generally accepted accounting principles.",
          "bbox": [
            446.0,
            2613.0,
            2144.0,
            2672.0
          ],
          "confidence": 0.9943995475769043
        },
        {
          "text": "1.30 \"Governmental Authority\" shall mean any court, agency, authority, department, regulatory body or other",
          "bbox": [
            444.0,
            2739.0,
            3029.0,
            2800.0
          ],
          "confidence": 0.9906880855560303
        },
        {
          "text": "instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political",
          "bbox": [
            279.0,
            2814.0,
            3027.0,
            2865.0
          ],
          "confidence": 0.99421226978302
        },
        {
          "text": "subdivision of any such government or any supranational organization of which any such country is a member, which has competent.",
          "bbox": [
            283.0,
            2885.0,
            3027.0,
            2929.0
          ],
          "confidence": 0.9955881834030151
        },
        {
          "text": "and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this",
          "bbox": [
            283.0,
            2951.0,
            3025.0,
            2995.0
          ],
          "confidence": 0.9951909184455872
        },
        {
          "text": "Agreement.",
          "bbox": [
            281.0,
            3019.0,
            520.0,
            3063.0
          ],
          "confidence": 0.9976062774658203
        },
        {
          "text": "4",
          "bbox": [
            1642.0,
            3200.0,
            1666.0,
            3225.0
          ],
          "confidence": 0.8676274418830872
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            3507.0,
            2275.0,
            3532.0
          ],
          "confidence": 0.9973365664482117
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9947719573974609
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 9,
          "bbox": [
            1031.0,
            3507.0,
            2275.0,
            3532.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Audit Rights_10_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Dova shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed over- payment for that audited period in excess of [***] of the amounts properly determined, in which case, Valeant shall reimburse Dova for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.",
      "page_number": 10,
      "words": [
        {
          "text": "1.31 \"Gross to Net Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the net",
          "bbox": [
            446.0,
            497.0,
            3029.0,
            548.0
          ],
          "confidence": 0.9874702095985413
        },
        {
          "text": "sales of the SKU of the Product in the Territory for an applicable period (based on the gross-to-net discounts for all sales of such",
          "bbox": [
            279.0,
            570.0,
            3027.0,
            619.0
          ],
          "confidence": 0.9992752075195312
        },
        {
          "text": "SKU of the Product (i.e., sales attributable to the Specialty, as well as all other sales of such SKU of the Product), and (ii) the",
          "bbox": [
            277.0,
            634.0,
            3025.0,
            685.0
          ],
          "confidence": 0.989626944065094
        },
        {
          "text": "denominator of which is gross sales of such SKU of the Product in the Territory for an applicable period, in each case, as",
          "bbox": [
            275.0,
            700.0,
            3029.0,
            757.0
          ],
          "confidence": 0.9913815855979919
        },
        {
          "text": "determined in accordance with Dova's revenue recognition policies, which is in accordance with GAAP (on a consistent basis), for",
          "bbox": [
            283.0,
            773.0,
            3025.0,
            817.0
          ],
          "confidence": 0.9897457361221313
        },
        {
          "text": "quarterly financial reporting purposes, as reported in Dova's quarterly filings with the U.S. Securities Exchange Commission.",
          "bbox": [
            283.0,
            839.0,
            2884.0,
            888.0
          ],
          "confidence": 0.9902921915054321
        },
        {
          "text": "1.32 \"Indemnified Party'' shall have the meaning set forth in Section 11.3..",
          "bbox": [
            450.0,
            958.0,
            2017.0,
            1007.0
          ],
          "confidence": 0.965660572052002
        },
        {
          "text": "1.33 \"Indemnifying Party' shall have the meaning set forth in Section 11.3..",
          "bbox": [
            448.0,
            1082.0,
            2046.0,
            1135.0
          ],
          "confidence": 0.9826773405075073
        },
        {
          "text": "1.34 \"Intellectual Property\" shall have the meaning set forth in Section 8.1.2",
          "bbox": [
            446.0,
            1208.0,
            2101.0,
            1263.0
          ],
          "confidence": 0.9879571795463562
        },
        {
          "text": "1.35 \"Intermediary\" shall mean any wholesaler or distributor who sells Product to Retail Pharmacies and Non-Retail",
          "bbox": [
            450.0,
            1338.0,
            3029.0,
            1387.0
          ],
          "confidence": 0.9892066717147827
        },
        {
          "text": "Institutions, but not patients, and with which Dova (or its Affiliates) has entered into an agreement or otherwise has arrangements.",
          "bbox": [
            279.0,
            1407.0,
            2983.0,
            1458.0
          ],
          "confidence": 0.9925985336303711
        },
        {
          "text": "1.36 \"Inventions\"' shall have the meaning set forth in Section 8.1.2.",
          "bbox": [
            450.0,
            1529.0,
            1867.0,
            1579.0
          ],
          "confidence": 0.9816356301307678
        },
        {
          "text": "1.37 \"JSC\" shall have the meaning set forth in Section 3.1.",
          "bbox": [
            450.0,
            1656.0,
            1680.0,
            1705.0
          ],
          "confidence": 0.979685366153717
        },
        {
          "text": "1.38 \"Know-How\"' shall mean information, whether or not in written form, including biological, chemical, pharmacological,",
          "bbox": [
            446.0,
            1782.0,
            3023.0,
            1833.0
          ],
          "confidence": 0.9908992648124695
        },
        {
          "text": "toxicological, medical or clinical, analytical, quality, manufacturing, research, or sales and marketing information, including",
          "bbox": [
            279.0,
            1851.0,
            3027.0,
            1906.0
          ],
          "confidence": 0.9901236295700073
        },
        {
          "text": "processes, methods, procedures, techniques, plans, programs and data.",
          "bbox": [
            281.0,
            1922.0,
            1785.0,
            1972.0
          ],
          "confidence": 0.9997182488441467
        },
        {
          "text": "1.39 \"Losses\" shall mean any and all amounts paid or payable to Third Parties with respect to a Claim (including any and.",
          "bbox": [
            446.0,
            2039.0,
            3025.0,
            2094.0
          ],
          "confidence": 0.9901546835899353
        },
        {
          "text": "all losses, damages, obligations, liabilities, fines, fees, penalties, awards, judgments, interest), together with all documented out-of-",
          "bbox": [
            283.0,
            2114.0,
            3023.0,
            2164.0
          ],
          "confidence": 0.9965105056762695
        },
        {
          "text": "pocket costs and expenses, including attorney's fees, reasonably incurred..",
          "bbox": [
            279.0,
            2178.0,
            1831.0,
            2229.0
          ],
          "confidence": 0.9926494359970093
        },
        {
          "text": "1.40 *Net Sales\"' shall mean, for an applicable period, the aggregate amount, without duplication, equal to the Specialty",
          "bbox": [
            444.0,
            2299.0,
            3021.0,
            2355.0
          ],
          "confidence": 0.989584743976593
        },
        {
          "text": "Pharmacy Net Sales for each SKU, the Retail Net Sales for each SKU, if any, and the Non-Retail Net Sales for each SKU.",
          "bbox": [
            281.0,
            2372.0,
            2893.0,
            2421.0
          ],
          "confidence": 0.9925589561462402
        },
        {
          "text": "1.41 *Non-Retail Institution' shall mean any institution (other than the Specialty Pharmacies, Retail Pharmacies and",
          "bbox": [
            446.0,
            2492.0,
            3029.0,
            2544.0
          ],
          "confidence": 0.9886279106140137
        },
        {
          "text": "Intermediaries) to which Dova (or its Affiliates or its Intermediaries) sells and/or ships units of Product during the Term, which shall",
          "bbox": [
            279.0,
            2566.0,
            3027.0,
            2613.0
          ],
          "confidence": 0.9940993189811707
        },
        {
          "text": "include group purchasing organizations (GPOs), hospitals, clinics, long term care facilities and any outlets that are a member of an",
          "bbox": [
            277.0,
            2631.0,
            3027.0,
            2684.0
          ],
          "confidence": 0.9924531579017639
        },
        {
          "text": "Integrated Delivery Network (IDN), and with which Dova or its Affiliates do not have data agreements which enables Dova to",
          "bbox": [
            281.0,
            2703.0,
            3025.0,
            2746.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "track shipments of Product from such institution to patients based on the Target Professional prescribing such Product.",
          "bbox": [
            283.0,
            2768.0,
            2755.0,
            2812.0
          ],
          "confidence": 0.9929245114326477
        },
        {
          "text": "1.42 \"Non-Retail Net Sales'' shall mean, for each SKU of the Product:.",
          "bbox": [
            449.0,
            2887.0,
            1979.0,
            2933.0
          ],
          "confidence": 0.9764129519462585
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "bbox": [
            370.0,
            3331.0,
            2938.0,
            3370.0
          ],
          "confidence": 0.994901180267334
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            3384.0,
            2276.0,
            3410.0
          ],
          "confidence": 0.9962199926376343
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9899002313613892
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 10,
          "bbox": [
            370.0,
            3331.0,
            2938.0,
            3370.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 10,
          "bbox": [
            1031.0,
            3384.0,
            2276.0,
            3410.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Uncapped Liability_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a party’s liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "THE FOREGOING SENTENCE SHALL NOT LIMIT (1) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.1 OR 11.2, AS APPLICABLE, OR (2) DAMAGES AVAILABLE FOR A PARTY'S BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE 9.",
      "page_number": 4,
      "words": [
        {
          "text": "12.3 Other Early Termination.",
          "bbox": [
            254.0,
            261.0,
            941.0,
            307.0
          ],
          "confidence": 0.9768185019493103
        },
        {
          "text": "42",
          "bbox": [
            2838.0,
            258.0,
            2902.0,
            311.0
          ],
          "confidence": 0.9997340440750122
        },
        {
          "text": "12.4 Effects of Termination.",
          "bbox": [
            254.0,
            375.0,
            892.0,
            420.0
          ],
          "confidence": 0.9832412004470825
        },
        {
          "text": "42",
          "bbox": [
            2838.0,
            369.0,
            2902.0,
            422.0
          ],
          "confidence": 0.9996985197067261
        },
        {
          "text": "12.5 Tail Period.",
          "bbox": [
            254.0,
            484.0,
            624.0,
            532.0
          ],
          "confidence": 0.9998460412025452
        },
        {
          "text": "42",
          "bbox": [
            2837.0,
            482.0,
            2904.0,
            535.0
          ],
          "confidence": 0.9995782971382141
        },
        {
          "text": "CHTII NHHN SRH LINIHXI SIHL HO NOISIIA DLIIdNRT R D***] CHLVNNISHE HIV SNOISSINR LSHNOHN ARITRILNHEHHNOP V RL LNHANNS",
          "bbox": [
            373.0,
            892.0,
            2934.0,
            923.0
          ],
          "confidence": 0.5245147347450256
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            937.0,
            2278.0,
            968.0
          ],
          "confidence": 0.9959927797317505
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9859865307807922
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 4,
          "bbox": [
            1030.0,
            937.0,
            2278.0,
            968.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Uncapped Liability_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a party’s liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "THE FOREGOING SENTENCE SHALL NOT LIMIT (1) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.1 OR 11.2, AS APPLICABLE, OR (2) DAMAGES AVAILABLE FOR A PARTY'S BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE 9.",
      "page_number": 5,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ],
          "confidence": 0.9835495948791504
        },
        {
          "text": "(continued)",
          "bbox": [
            1539.0,
            353.0,
            1778.0,
            404.0
          ],
          "confidence": 0.9998818039894104
        },
        {
          "text": "12.6 Survival.",
          "bbox": [
            254.0,
            628.0,
            569.0,
            676.0
          ],
          "confidence": 0.9681076407432556
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            625.0,
            2904.0,
            678.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ],
          "confidence": 0.9842489957809448
        },
        {
          "text": "43",
          "bbox": [
            2837.0,
            738.0,
            2902.0,
            791.0
          ],
          "confidence": 0.9999362230300903
        },
        {
          "text": "13.1 Force Majeure.",
          "bbox": [
            254.0,
            851.0,
            723.0,
            903.0
          ],
          "confidence": 0.9955340027809143
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            850.0,
            2902.0,
            903.0
          ],
          "confidence": 0.9999621510505676
        },
        {
          "text": "13.2 Assignment.",
          "bbox": [
            254.0,
            967.0,
            647.0,
            1014.0
          ],
          "confidence": 0.994281530380249
        },
        {
          "text": "43",
          "bbox": [
            2838.0,
            961.0,
            2904.0,
            1016.0
          ],
          "confidence": 0.9998818635940552
        },
        {
          "text": "13.3 Severability..",
          "bbox": [
            254.0,
            1076.0,
            653.0,
            1126.0
          ],
          "confidence": 0.9700116515159607
        },
        {
          "text": "44",
          "bbox": [
            2838.0,
            1074.0,
            2904.0,
            1127.0
          ],
          "confidence": 0.9998847842216492
        },
        {
          "text": "13.4 Notices.",
          "bbox": [
            253.0,
            1187.0,
            553.0,
            1239.0
          ],
          "confidence": 0.9727678298950195
        },
        {
          "text": "44",
          "bbox": [
            2840.0,
            1190.0,
            2902.0,
            1237.0
          ],
          "confidence": 0.9999162554740906
        },
        {
          "text": "13.5 Governing Law.",
          "bbox": [
            254.0,
            1301.0,
            729.0,
            1352.0
          ],
          "confidence": 0.9988176226615906
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1297.0,
            2904.0,
            1352.0
          ],
          "confidence": 0.9997564554214478
        },
        {
          "text": "13.6 Dispute Resolution.",
          "bbox": [
            254.0,
            1416.0,
            827.0,
            1462.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1411.0,
            2904.0,
            1464.0
          ],
          "confidence": 0.9998887777328491
        },
        {
          "text": "13.7 Waiver of Jury Trial.",
          "bbox": [
            254.0,
            1528.0,
            845.0,
            1573.0
          ],
          "confidence": 0.9974088668823242
        },
        {
          "text": "45",
          "bbox": [
            2838.0,
            1522.0,
            2904.0,
            1577.0
          ],
          "confidence": 0.9998284578323364
        },
        {
          "text": "13.8 Entire Agreement: Amendments.",
          "bbox": [
            256.0,
            1643.0,
            1126.0,
            1683.0
          ],
          "confidence": 0.9839103817939758
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1634.0,
            2904.0,
            1688.0
          ],
          "confidence": 0.9998567700386047
        },
        {
          "text": "13.9 Headings.",
          "bbox": [
            252.0,
            1747.0,
            589.0,
            1804.0
          ],
          "confidence": 0.9636107087135315
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1747.0,
            2904.0,
            1800.0
          ],
          "confidence": 0.9998417496681213
        },
        {
          "text": "13.10 Independent Contractors..",
          "bbox": [
            256.0,
            1866.0,
            986.0,
            1911.0
          ],
          "confidence": 0.981669545173645
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            1860.0,
            2904.0,
            1913.0
          ],
          "confidence": 0.9998571872711182
        },
        {
          "text": "13.11 Third Party Beneficiaries..",
          "bbox": [
            254.0,
            1977.0,
            986.0,
            2023.0
          ],
          "confidence": 0.9783740043640137
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            1972.0,
            2904.0,
            2025.0
          ],
          "confidence": 0.9998377561569214
        },
        {
          "text": "13.12 Waiver.",
          "bbox": [
            250.0,
            2085.0,
            568.0,
            2140.0
          ],
          "confidence": 0.9982175230979919
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2083.0,
            2904.0,
            2138.0
          ],
          "confidence": 0.9998304843902588
        },
        {
          "text": "13.13 Cumulative Remedies..",
          "bbox": [
            252.0,
            2200.0,
            919.0,
            2248.0
          ],
          "confidence": 0.9648547768592834
        },
        {
          "text": "46",
          "bbox": [
            2837.0,
            2196.0,
            2904.0,
            2249.0
          ],
          "confidence": 0.9998633861541748
        },
        {
          "text": "13.14 Waiver of Rule of Construction.",
          "bbox": [
            254.0,
            2313.0,
            1129.0,
            2359.0
          ],
          "confidence": 0.9997852444648743
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2308.0,
            2904.0,
            2363.0
          ],
          "confidence": 0.9998478293418884
        },
        {
          "text": "13.15 Use of Names.",
          "bbox": [
            252.0,
            2419.0,
            734.0,
            2474.0
          ],
          "confidence": 0.9992044568061829
        },
        {
          "text": "46",
          "bbox": [
            2838.0,
            2421.0,
            2904.0,
            2474.0
          ],
          "confidence": 0.9998313188552856
        },
        {
          "text": "13.16 Further Actions and Documents.",
          "bbox": [
            254.0,
            2538.0,
            1146.0,
            2584.0
          ],
          "confidence": 0.9997870922088623
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2533.0,
            2902.0,
            2586.0
          ],
          "confidence": 0.9999172687530518
        },
        {
          "text": "13.17 Certain Conventions.",
          "bbox": [
            254.0,
            2650.0,
            879.0,
            2697.0
          ],
          "confidence": 0.9826027154922485
        },
        {
          "text": "47",
          "bbox": [
            2838.0,
            2646.0,
            2902.0,
            2699.0
          ],
          "confidence": 0.7881843447685242
        },
        {
          "text": "13.18 Counterparts",
          "bbox": [
            255.0,
            2763.0,
            709.0,
            2811.0
          ],
          "confidence": 0.9997767210006714
        },
        {
          "text": "47",
          "bbox": [
            2837.0,
            2757.0,
            2902.0,
            2810.0
          ],
          "confidence": 0.9999107718467712
        },
        {
          "text": "i",
          "bbox": [
            1628.0,
            3083.0,
            1666.0,
            3134.0
          ],
          "confidence": 0.699363112449646
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ],
          "confidence": 0.9872980713844299
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9875343441963196
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 5,
          "bbox": [
            1370.0,
            287.0,
            1947.0,
            329.0
          ]
        },
        {
          "text": "LE 13 MISCELLANEOUS",
          "page": 5,
          "bbox": [
            252.0,
            744.0,
            843.0,
            786.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 5,
          "bbox": [
            1030.0,
            3307.0,
            2276.0,
            3339.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Cap On Liability_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2800.0,
            283.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9779579043388367
        },
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ],
          "confidence": 0.9996495842933655
        },
        {
          "text": "by and between",
          "bbox": [
            1477.0,
            872.0,
            1834.0,
            915.0
          ],
          "confidence": 0.9997774958610535
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ],
          "confidence": 0.9989398121833801
        },
        {
          "text": "and",
          "bbox": [
            1605.0,
            1278.0,
            1701.0,
            1331.0
          ],
          "confidence": 0.9980132579803467
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ],
          "confidence": 0.9993768334388733
        },
        {
          "text": "September 26, 2018",
          "bbox": [
            1419.0,
            1637.0,
            1883.0,
            1692.0
          ],
          "confidence": 0.9950999021530151
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ],
          "confidence": 0.989909827709198
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ],
          "confidence": 0.994059681892395
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9876725673675537
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1243.0,
            634.0,
            2066.0,
            676.0
          ]
        },
        {
          "text": "DOVA PHARMACEUTICALS, INC",
          "page": 0,
          "bbox": [
            1220.0,
            1104.0,
            2081.0,
            1148.0
          ]
        },
        {
          "text": "VALEANT PHARMACEUTICALS NORTH AMERICA LLC",
          "page": 0,
          "bbox": [
            933.0,
            1462.0,
            2378.0,
            1504.0
          ]
        },
        {
          "text": "SUBJECT TO A CONFIDENTIALITY REOUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED",
          "page": 0,
          "bbox": [
            373.0,
            2328.0,
            2936.0,
            2359.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 0,
          "bbox": [
            1031.0,
            2377.0,
            2275.0,
            2403.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Cap On Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ],
          "confidence": 0.9780283570289612
        },
        {
          "text": "Page",
          "bbox": [
            2776.0,
            688.0,
            2901.0,
            750.0
          ],
          "confidence": 0.9999327659606934
        },
        {
          "text": "1",
          "bbox": [
            2864.0,
            917.0,
            2902.0,
            968.0
          ],
          "confidence": 0.9995635151863098
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ],
          "confidence": 0.9859031438827515
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ],
          "confidence": 0.9988932013511658
        },
        {
          "text": "8",
          "bbox": [
            2864.0,
            1029.0,
            2902.0,
            1082.0
          ],
          "confidence": 0.9996312856674194
        },
        {
          "text": "2.1 Engagement; Grant of Rights.",
          "bbox": [
            254.0,
            1142.0,
            1035.0,
            1193.0
          ],
          "confidence": 0.9930101633071899
        },
        {
          "text": "8",
          "bbox": [
            2866.0,
            1142.0,
            2904.0,
            1193.0
          ],
          "confidence": 0.9996554851531982
        },
        {
          "text": "2.2 Retention of Rights.",
          "bbox": [
            255.0,
            1255.0,
            803.0,
            1305.0
          ],
          "confidence": 0.9952546954154968
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1254.0,
            2902.0,
            1305.0
          ],
          "confidence": 0.99913090467453
        },
        {
          "text": "2.3 Non-Competition; Non-Solicitation.",
          "bbox": [
            255.0,
            1369.0,
            1155.0,
            1416.0
          ],
          "confidence": 0.9856934547424316
        },
        {
          "text": "9",
          "bbox": [
            2864.0,
            1365.0,
            2902.0,
            1418.0
          ],
          "confidence": 0.9992173910140991
        },
        {
          "text": "2.4 Dova Trademarks and Copyrights.",
          "bbox": [
            256.0,
            1482.0,
            1135.0,
            1528.0
          ],
          "confidence": 0.9905837178230286
        },
        {
          "text": "10",
          "bbox": [
            2837.0,
            1476.0,
            2904.0,
            1531.0
          ],
          "confidence": 0.9995734095573425
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ],
          "confidence": 0.9954172968864441
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1592.0,
            2900.0,
            1641.0
          ],
          "confidence": 0.9997044801712036
        },
        {
          "text": "3.1 Formation of the JSC.",
          "bbox": [
            256.0,
            1707.0,
            839.0,
            1751.0
          ],
          "confidence": 0.992499589920044
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1705.0,
            2900.0,
            1754.0
          ],
          "confidence": 0.9998102188110352
        },
        {
          "text": "3.2 Meetings and Minutes..",
          "bbox": [
            255.0,
            1818.0,
            877.0,
            1866.0
          ],
          "confidence": 0.9774132370948792
        },
        {
          "text": "11",
          "bbox": [
            2840.0,
            1813.0,
            2902.0,
            1868.0
          ],
          "confidence": 0.9997932314872742
        },
        {
          "text": "3.3 Purpose of the JSC",
          "bbox": [
            256.0,
            1933.0,
            790.0,
            1975.0
          ],
          "confidence": 0.9881646633148193
        },
        {
          "text": "11",
          "bbox": [
            2842.0,
            1928.0,
            2900.0,
            1977.0
          ],
          "confidence": 0.9997947812080383
        },
        {
          "text": "3.4 Decision Making..",
          "bbox": [
            252.0,
            2035.0,
            751.0,
            2094.0
          ],
          "confidence": 0.954731285572052
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2037.0,
            2904.0,
            2090.0
          ],
          "confidence": 0.9999567270278931
        },
        {
          "text": "3.5 Marketing Sub-Committee.",
          "bbox": [
            255.0,
            2154.0,
            972.0,
            2204.0
          ],
          "confidence": 0.9678689241409302
        },
        {
          "text": "13",
          "bbox": [
            2835.0,
            2151.0,
            2902.0,
            2204.0
          ],
          "confidence": 0.9999614953994751
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ],
          "confidence": 0.999039351940155
        },
        {
          "text": "14",
          "bbox": [
            2838.0,
            2262.0,
            2904.0,
            2315.0
          ],
          "confidence": 0.9999129176139832
        },
        {
          "text": "4.1 Valeant Activities.",
          "bbox": [
            254.0,
            2379.0,
            756.0,
            2427.0
          ],
          "confidence": 0.9994301199913025
        },
        {
          "text": "14",
          "bbox": [
            2835.0,
            2376.0,
            2904.0,
            2429.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "4.2 Detailing.",
          "bbox": [
            251.0,
            2485.0,
            561.0,
            2544.0
          ],
          "confidence": 0.947688102722168
        },
        {
          "text": "15",
          "bbox": [
            2837.0,
            2485.0,
            2904.0,
            2542.0
          ],
          "confidence": 0.9998620748519897
        },
        {
          "text": "4.3 Compliance with Applicable Law.",
          "bbox": [
            254.0,
            2604.0,
            1097.0,
            2652.0
          ],
          "confidence": 0.999403178691864
        },
        {
          "text": "17",
          "bbox": [
            2837.0,
            2598.0,
            2904.0,
            2653.0
          ],
          "confidence": 0.9998419284820557
        },
        {
          "text": "4.4 Field Force Personnel Training; Product Materials..",
          "bbox": [
            256.0,
            2717.0,
            1515.0,
            2761.0
          ],
          "confidence": 0.9813730120658875
        },
        {
          "text": "19",
          "bbox": [
            2835.0,
            2712.0,
            2904.0,
            2765.0
          ],
          "confidence": 0.9997812509536743
        },
        {
          "text": "4.5 Provisions Related to Field Force Personnel",
          "bbox": [
            254.0,
            2829.0,
            1367.0,
            2874.0
          ],
          "confidence": 0.999675989151001
        },
        {
          "text": "21",
          "bbox": [
            2835.0,
            2825.0,
            2900.0,
            2878.0
          ],
          "confidence": 0.9999203681945801
        },
        {
          "text": "4.6 Responsibility for Valeant Activity Costs and Expenses..",
          "bbox": [
            256.0,
            2940.0,
            1628.0,
            2988.0
          ],
          "confidence": 0.983078122138977
        },
        {
          "text": "22",
          "bbox": [
            2835.0,
            2937.0,
            2902.0,
            2990.0
          ],
          "confidence": 0.9998236894607544
        },
        {
          "text": "4.7 Data Sharing.",
          "bbox": [
            252.0,
            3048.0,
            653.0,
            3105.0
          ],
          "confidence": 0.975680947303772
        },
        {
          "text": "22",
          "bbox": [
            2838.0,
            3052.0,
            2900.0,
            3099.0
          ],
          "confidence": 0.9997785091400146
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ],
          "confidence": 0.9930562376976013
        },
        {
          "text": "MATTERS",
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ],
          "confidence": 0.999487042427063
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3231.0,
            2902.0,
            3286.0
          ],
          "confidence": 0.999907374382019
        },
        {
          "text": "5.1 Dova Responsibility",
          "bbox": [
            256.0,
            3349.0,
            814.0,
            3395.0
          ],
          "confidence": 0.9984672665596008
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3342.0,
            2902.0,
            3397.0
          ],
          "confidence": 0.9999030232429504
        },
        {
          "text": "5.2 Valeant Involvement.",
          "bbox": [
            256.0,
            3463.0,
            827.0,
            3503.0
          ],
          "confidence": 0.9985610842704773
        },
        {
          "text": "23",
          "bbox": [
            2835.0,
            3456.0,
            2902.0,
            3508.0
          ],
          "confidence": 0.9999406337738037
        },
        {
          "text": "23",
          "bbox": [
            2834.0,
            3564.0,
            2904.0,
            3624.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "5.3 Inspections.",
          "bbox": [
            256.0,
            3576.0,
            609.0,
            3620.0
          ],
          "confidence": 0.9983316659927368
        },
        {
          "text": "5.4 Pharmacovigilance.",
          "bbox": [
            254.0,
            3684.0,
            783.0,
            3732.0
          ],
          "confidence": 0.9932737946510315
        },
        {
          "text": "24",
          "bbox": [
            2837.0,
            3680.0,
            2904.0,
            3733.0
          ],
          "confidence": 0.9999386668205261
        },
        {
          "text": "5.5 Unsolicited Requests for Medical Information.",
          "bbox": [
            254.0,
            3797.0,
            1414.0,
            3843.0
          ],
          "confidence": 0.9851503372192383
        },
        {
          "text": "24",
          "bbox": [
            2835.0,
            3792.0,
            2904.0,
            3845.0
          ],
          "confidence": 0.9999282956123352
        },
        {
          "text": "5.6 Recalls and Market Withdrawals",
          "bbox": [
            257.0,
            3911.0,
            1115.0,
            3953.0
          ],
          "confidence": 0.9952821135520935
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            3903.0,
            2904.0,
            3958.0
          ],
          "confidence": 0.9998209476470947
        },
        {
          "text": "5.7 Certain Reporting Responsibilities",
          "bbox": [
            256.0,
            4026.0,
            1153.0,
            4068.0
          ],
          "confidence": 0.9995793700218201
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4017.0,
            2904.0,
            4069.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "5.8 Booking of Sales Revenues.",
          "bbox": [
            254.0,
            4132.0,
            993.0,
            4181.0
          ],
          "confidence": 0.9986859560012817
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4128.0,
            2904.0,
            4183.0
          ],
          "confidence": 0.9998403787612915
        },
        {
          "text": "5.9 Returns.",
          "bbox": [
            253.0,
            4243.0,
            539.0,
            4295.0
          ],
          "confidence": 0.9989113807678223
        },
        {
          "text": "25",
          "bbox": [
            2837.0,
            4239.0,
            2904.0,
            4296.0
          ],
          "confidence": 0.9997888803482056
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4477.0
          ],
          "confidence": 0.9973026514053345
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1374.0,
            285.0,
            1943.0,
            322.0
          ]
        },
        {
          "text": "ARTICLE 1 DEFINITIONS",
          "page": 1,
          "bbox": [
            419.0,
            948.0,
            1028.0,
            990.0
          ]
        },
        {
          "text": "LE 2 RIGHTS AND OBLIGATIONS",
          "page": 1,
          "bbox": [
            252.0,
            1034.0,
            1059.0,
            1075.0
          ]
        },
        {
          "text": "LE 3 JOINT STEERING COMMITTEE",
          "page": 1,
          "bbox": [
            254.0,
            1595.0,
            1124.0,
            1639.0
          ]
        },
        {
          "text": "LE 4 VALEANT ACTIVITIES FOR THE PRODUCT",
          "page": 1,
          "bbox": [
            252.0,
            2270.0,
            1421.0,
            2312.0
          ]
        },
        {
          "text": "LE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL",
          "page": 1,
          "bbox": [
            250.0,
            3165.0,
            1876.0,
            3211.0
          ]
        },
        {
          "text": "MATTERS",
          "page": 1,
          "bbox": [
            426.0,
            3240.0,
            658.0,
            3278.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Cap On Liability_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN (OTHER THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4), IN NO EVENT SHALL DOVA (OR ITS AFFILIATES) OR VALEANT (OR ITS AFFILIATES) BE LIABLE TO THE OTHER OR ANY OF THE OTHER PARTY'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Cap On Liability_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN (OTHER THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4), IN NO EVENT SHALL DOVA (OR ITS AFFILIATES) OR VALEANT (OR ITS AFFILIATES) BE LIABLE TO THE OTHER OR ANY OF THE OTHER PARTY'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Liquidated Damages_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
      "answer_text": "Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Liquidated Damages_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
      "answer_text": "Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Insurance_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly situated.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Insurance_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly situated.",
      "page_number": 7,
      "words": [
        {
          "text": "ARTICLE 1",
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ],
          "confidence": 0.998056173324585
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ],
          "confidence": 0.9989469051361084
        },
        {
          "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
          "bbox": [
            450.0,
            665.0,
            3025.0,
            714.0
          ],
          "confidence": 0.9817363619804382
        },
        {
          "text": "time to time, and the regulations promulgated thereunder..",
          "bbox": [
            279.0,
            733.0,
            1468.0,
            784.0
          ],
          "confidence": 0.9895068407058716
        },
        {
          "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
          "bbox": [
            446.0,
            852.0,
            3025.0,
            910.0
          ],
          "confidence": 0.9930065274238586
        },
        {
          "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
          "bbox": [
            279.0,
            928.0,
            3025.0,
            974.0
          ],
          "confidence": 0.9940690994262695
        },
        {
          "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
          "bbox": [
            277.0,
            992.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9965134263038635
        },
        {
          "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
          "bbox": [
            283.0,
            1065.0,
            3027.0,
            1109.0
          ],
          "confidence": 0.9922182559967041
        },
        {
          "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
          "bbox": [
            279.0,
            1127.0,
            2335.0,
            1173.0
          ],
          "confidence": 0.9899165034294128
        },
        {
          "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
          "bbox": [
            446.0,
            1248.0,
            3023.0,
            1299.0
          ],
          "confidence": 0.9931779503822327
        },
        {
          "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
          "bbox": [
            277.0,
            1319.0,
            3025.0,
            1371.0
          ],
          "confidence": 0.9981216192245483
        },
        {
          "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
          "bbox": [
            275.0,
            1387.0,
            3031.0,
            1438.0
          ],
          "confidence": 0.9915010929107666
        },
        {
          "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
          "bbox": [
            279.0,
            1455.0,
            3029.0,
            1504.0
          ],
          "confidence": 0.9891557097434998
        },
        {
          "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
          "bbox": [
            277.0,
            1518.0,
            2093.0,
            1572.0
          ],
          "confidence": 0.9916882514953613
        },
        {
          "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
          "bbox": [
            448.0,
            1641.0,
            2228.0,
            1692.0
          ],
          "confidence": 0.9855000376701355
        },
        {
          "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
          "bbox": [
            451.0,
            1771.0,
            2034.0,
            1815.0
          ],
          "confidence": 0.984380841255188
        },
        {
          "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
          "bbox": [
            448.0,
            1895.0,
            3025.0,
            1944.0
          ],
          "confidence": 0.9930753111839294
        },
        {
          "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
          "bbox": [
            279.0,
            1964.0,
            3025.0,
            2016.0
          ],
          "confidence": 0.9947968125343323
        },
        {
          "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
          "bbox": [
            277.0,
            2032.0,
            3025.0,
            2083.0
          ],
          "confidence": 0.9997901320457458
        },
        {
          "text": "the Product with regard to Target Professionals in the Specialty",
          "bbox": [
            277.0,
            2098.0,
            1606.0,
            2149.0
          ],
          "confidence": 0.9994950294494629
        },
        {
          "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
          "bbox": [
            446.0,
            2220.0,
            3027.0,
            2271.0
          ],
          "confidence": 0.991833508014679
        },
        {
          "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
          "bbox": [
            283.0,
            2295.0,
            3025.0,
            2339.0
          ],
          "confidence": 0.9922526478767395
        },
        {
          "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
          "bbox": [
            277.0,
            2423.0,
            3027.0,
            2474.0
          ],
          "confidence": 0.9902378916740417
        },
        {
          "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
          "bbox": [
            277.0,
            2491.0,
            3027.0,
            2542.0
          ],
          "confidence": 0.9841631650924683
        },
        {
          "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
          "bbox": [
            279.0,
            2560.0,
            3025.0,
            2604.0
          ],
          "confidence": 0.990945041179657
        },
        {
          "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
          "bbox": [
            277.0,
            2622.0,
            3027.0,
            2673.0
          ],
          "confidence": 0.9925962686538696
        },
        {
          "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
          "bbox": [
            277.0,
            2692.0,
            3023.0,
            2743.0
          ],
          "confidence": 0.9953201413154602
        },
        {
          "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
          "bbox": [
            281.0,
            2763.0,
            3021.0,
            2807.0
          ],
          "confidence": 0.9940048456192017
        },
        {
          "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
          "bbox": [
            277.0,
            2821.0,
            2855.0,
            2880.0
          ],
          "confidence": 0.9916945695877075
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3006.0,
            1666.0,
            3044.0
          ],
          "confidence": 0.9821695685386658
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ],
          "confidence": 0.5431110262870789
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ],
          "confidence": 0.9969194531440735
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9946284294128418
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 1",
          "page": 7,
          "bbox": [
            1513.0,
            495.0,
            1791.0,
            534.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 7,
          "bbox": [
            1479.0,
            552.0,
            1840.0,
            590.0
          ]
        },
        {
          "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
          "page": 7,
          "bbox": [
            373.0,
            3267.0,
            2938.0,
            3304.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
          "page": 7,
          "bbox": [
            1030.0,
            3315.0,
            2278.0,
            3346.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Covenant Not To Sue_6",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights.",
      "page_number": 6,
      "words": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ],
          "confidence": 0.9996771216392517
        },
        {
          "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
          "bbox": [
            446.0,
            616.0,
            3027.0,
            667.0
          ],
          "confidence": 0.986116886138916
        },
        {
          "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
          "bbox": [
            281.0,
            689.0,
            3025.0,
            733.0
          ],
          "confidence": 0.9768568873405457
        },
        {
          "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
          "bbox": [
            279.0,
            753.0,
            3027.0,
            802.0
          ],
          "confidence": 0.9899930357933044
        },
        {
          "text": "and together as the \"Parties\"",
          "bbox": [
            281.0,
            817.0,
            906.0,
            868.0
          ],
          "confidence": 0.9791926145553589
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ],
          "confidence": 0.99937504529953
        },
        {
          "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
          "bbox": [
            446.0,
            1058.0,
            2878.0,
            1118.0
          ],
          "confidence": 0.9954515099525452
        },
        {
          "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
          "bbox": [
            451.0,
            1188.0,
            3021.0,
            1232.0
          ],
          "confidence": 0.989766001701355
        },
        {
          "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
          "bbox": [
            281.0,
            1254.0,
            3027.0,
            1303.0
          ],
          "confidence": 0.9896340370178223
        },
        {
          "text": "activities, for the Product in the Territory;",
          "bbox": [
            279.0,
            1317.0,
            1138.0,
            1372.0
          ],
          "confidence": 0.9894087314605713
        },
        {
          "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
          "bbox": [
            446.0,
            1444.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9769154787063599
        },
        {
          "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
          "bbox": [
            283.0,
            1513.0,
            2539.0,
            1557.0
          ],
          "confidence": 0.9927414655685425
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ],
          "confidence": 0.9983646273612976
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1472.0,
            4479.0
          ],
          "confidence": 0.9886208176612854
        }
      ],
      "nearby_headers": [
        {
          "text": "CO-PROMOTION AGREEMENT",
          "page": 6,
          "bbox": [
            1242.0,
            497.0,
            2064.0,
            539.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 6,
          "bbox": [
            1517.0,
            941.0,
            1789.0,
            985.0
          ]
        },
        {
          "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
          "page": 6,
          "bbox": [
            1030.0,
            1831.0,
            2278.0,
            1862.0
          ]
        }
      ]
    },
    {
      "id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Covenant Not To Sue_13",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "During the Term, Valeant will not contest the ownership of the Dova Trademarks and Copyrights, their validity, or the validity of any registration therefor.",
      "page_number": 13,
      "words": [
        {
          "text": "(i) the number of units of such SKU of the Product shipped from the Specialty Pharmacies to all patients based on prescriptions.",
          "bbox": [
            292.0,
            495.0,
            3025.0,
            546.0
          ],
          "confidence": 0.9927263259887695
        },
        {
          "text": "written by the Specialty in the Territory during an applicable period (as determined by data reported pursuant to agreements",
          "bbox": [
            292.0,
            563.0,
            3029.0,
            614.0
          ],
          "confidence": 0.9914117455482483
        },
        {
          "text": "between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable); and",
          "bbox": [
            288.0,
            629.0,
            2505.0,
            678.0
          ],
          "confidence": 0.9959461092948914
        },
        {
          "text": "MULTIPLIED BY",
          "bbox": [
            450.0,
            755.0,
            843.0,
            793.0
          ],
          "confidence": 0.978923499584198
        },
        {
          "text": "(ii) the applicable WAC for such SKU of the Product for the applicable period",
          "bbox": [
            295.0,
            875.0,
            1948.0,
            925.0
          ],
          "confidence": 0.9939121603965759
        },
        {
          "text": "MULTIPLIED BY",
          "bbox": [
            290.0,
            1000.0,
            685.0,
            1038.0
          ],
          "confidence": 0.9972622394561768
        },
        {
          "text": "(iii) the Gross to Net Fraction for such SKU of the Product for the applicable period.",
          "bbox": [
            292.0,
            1120.0,
            2074.0,
            1170.0
          ],
          "confidence": 0.9934074282646179
        },
        {
          "text": "1.59 \"Specialty Pharmacy'' shall mean those specialty pharmacies to which Dova (or its Affiliates) sells and/or ships units",
          "bbox": [
            451.0,
            1246.0,
            3021.0,
            1290.0
          ],
          "confidence": 0.9903354644775391
        },
        {
          "text": "of Product during the Term and for which Dova or its Affiliates have agreements with that include data provisions or provide for",
          "bbox": [
            279.0,
            1312.0,
            3027.0,
            1363.0
          ],
          "confidence": 0.9923442006111145
        },
        {
          "text": "separate data agreements which enables Dova to track shipments of Product from such Specialty Pharmacy to patients based on",
          "bbox": [
            279.0,
            1380.0,
            3025.0,
            1429.0
          ],
          "confidence": 0.9987753033638
        },
        {
          "text": "the Target Professional prescribing such Product..",
          "bbox": [
            281.0,
            1451.0,
            1305.0,
            1495.0
          ],
          "confidence": 0.9886035323143005
        },
        {
          "text": "1.60 \"Tail Period\"' shall mean the period commencing on the day after the last day of the Term and ending on the earlier of",
          "bbox": [
            448.0,
            1570.0,
            3030.0,
            1619.0
          ],
          "confidence": 0.9820379614830017
        },
        {
          "text": "(i) [***] and (ii) [***], unless terminated early pursuant to Section 2.3.1(a) of the Agreement.",
          "bbox": [
            281.0,
            1637.0,
            2251.0,
            1692.0
          ],
          "confidence": 0.9817354679107666
        },
        {
          "text": "1.61 \"Target Professionals\" shall mean physicians, nurse practitioners, physician assistants and any other medical",
          "bbox": [
            448.0,
            1763.0,
            3027.0,
            1813.0
          ],
          "confidence": 0.9948866963386536
        },
        {
          "text": "professionals in the Territory with prescribing authority (as authorized under Applicable Law) in the Territory for the Product.",
          "bbox": [
            285.0,
            1836.0,
            2893.0,
            1880.0
          ],
          "confidence": 0.9959443807601929
        },
        {
          "text": "1.62 \"Term\"' shall have the meaning set forth in Section 12.1..",
          "bbox": [
            448.0,
            1952.0,
            1727.0,
            2003.0
          ],
          "confidence": 0.9637503027915955
        },
        {
          "text": "1.63 \"Territory'' shall mean the United States of America and its territories and possessions.",
          "bbox": [
            448.0,
            2080.0,
            2387.0,
            2131.0
          ],
          "confidence": 0.9891149401664734
        },
        {
          "text": "1.64 \"Third Party(ies)\"' shall mean any person or entity other than Dova and Valeant and their respective Affiliates",
          "bbox": [
            450.0,
            2207.0,
            2867.0,
            2257.0
          ],
          "confidence": 0.9815272688865662
        },
        {
          "text": "1.65 \"Third Party Agreements\" shall mean the agreements described on Schedule 1.65 hereto.",
          "bbox": [
            450.0,
            2334.0,
            2483.0,
            2383.0
          ],
          "confidence": 0.9881207942962646
        },
        {
          "text": "1.66 Valeant Activities\"' shall mean any and all promotional activities (including Detailing) conducted by Valeant to",
          "bbox": [
            446.0,
            2458.0,
            3023.0,
            2511.0
          ],
          "confidence": 0.9875069260597229
        },
        {
          "text": "encourage the appropriate use of the Product in the Specialty in the Field in the Territory in accordance with the terms of this",
          "bbox": [
            279.0,
            2531.0,
            3023.0,
            2578.0
          ],
          "confidence": 0.996233344078064
        },
        {
          "text": "Agreement.",
          "bbox": [
            279.0,
            2598.0,
            520.0,
            2642.0
          ],
          "confidence": 0.9588022232055664
        },
        {
          "text": "1.67 \"Valeant Property\" shall have the meaning set forth in Section 8.1.1.",
          "bbox": [
            450.0,
            2719.0,
            2016.0,
            2768.0
          ],
          "confidence": 0.9839121103286743
        },
        {
          "text": "1.68 \"WAC\" shall mean, for each SKU of the Product, Dova's list price for a unit of the SKU of the Product to",
          "bbox": [
            446.0,
            2843.0,
            3025.0,
            2895.0
          ],
          "confidence": 0.987399697303772
        },
        {
          "text": "wholesalers or direct purchasers in the Territory, as reported in wholesale price guides or other nationally recognized publications",
          "bbox": [
            279.0,
            2915.0,
            3025.0,
            2966.0
          ],
          "confidence": 0.9992479085922241
        },
        {
          "text": "of drug pricing data.n.",
          "bbox": [
            279.0,
            2982.0,
            698.0,
            3035.0
          ],
          "confidence": 0.950848400592804
        },
        {
          "text": "ARTICLE 2",
          "bbox": [
            1508.0,
            3105.0,
            1791.0,
            3149.0
          ],
          "confidence": 0.9970877170562744
        },
        {
          "text": "RIGHTS AND OBLIGATIONS",
          "bbox": [
            1281.0,
            3176.0,
            2026.0,
            3218.0
          ],
          "confidence": 0.9995303750038147
        },
        {
          "text": "2.1 Engagement; Grant of Rights. During the Term, subject to the terms and conditions of this Agreement, Dova",
          "bbox": [
            444.0,
            3295.0,
            3027.0,
            3346.0
          ],
          "confidence": 0.990031898021698
        },
        {
          "text": "hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product",
          "bbox": [
            277.0,
            3368.0,
            3031.0,
            3419.0
          ],
          "confidence": 0.9943550825119019
        },
        {
          "text": "in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account",
          "bbox": [
            281.0,
            3439.0,
            3029.0,
            3481.0
          ],
          "confidence": 0.9951699376106262
        },
        {
          "text": "management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance",
          "bbox": [
            275.0,
            3501.0,
            3027.0,
            3549.0
          ],
          "confidence": 0.991767942905426
        },
        {
          "text": "with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and",
          "bbox": [
            281.0,
            3572.0,
            3027.0,
            3616.0
          ],
          "confidence": 0.9915906190872192
        },
        {
          "text": "its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the",
          "bbox": [
            281.0,
            3638.0,
            3023.0,
            3682.0
          ],
          "confidence": 0.997682511806488
        },
        {
          "text": "Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if",
          "bbox": [
            281.0,
            3706.0,
            3029.0,
            3750.0
          ],
          "confidence": 0.9934957027435303
        },
        {
          "text": "agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or",
          "bbox": [
            279.0,
            3768.0,
            3027.0,
            3819.0
          ],
          "confidence": 0.9960676431655884
        },
        {
          "text": "outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights and obligations under this Section",
          "bbox": [
            281.0,
            3839.0,
            3025.0,
            3883.0
          ],
          "confidence": 0.9903414249420166
        },
        {
          "text": "2.1 are non-transferable, non-assignable, and non-delegable. Except to Affiliates of Valeant, Valeant shall not subcontract the",
          "bbox": [
            277.0,
            3900.0,
            3027.0,
            3951.0
          ],
          "confidence": 0.996195375919342
        },
        {
          "text": "Valeant Activities with any Third Party (including any contract sales force). Any obligation of Valeant under or pursuant to this.",
          "bbox": [
            277.0,
            3963.0,
            3027.0,
            4022.0
          ],
          "confidence": 0.9957552552223206
        },
        {
          "text": "Agreement may be satisfied, met or fulfilled, in whole or in part, at Valeant's sole and exclusive option, either by Valeant or its",
          "bbox": [
            281.0,
            4038.0,
            3025.0,
            4082.0
          ],
          "confidence": 0.9870525002479553
        },
        {
          "text": "Affiliates. Valeant guarantees the performance of all actions, agreements and obligations to be performed by its Affiliates under the",
          "bbox": [
            277.0,
            4101.0,
            3025.0,
            4152.0
          ],
          "confidence": 0.9952510595321655
        },
        {
          "text": "terms and conditions of this Agreement. For clarity, Valeant shall not have any license rights hereunder nor any rights to sublicense",
          "bbox": [
            281.0,
            4172.0,
            3023.0,
            4216.0
          ],
          "confidence": 0.9936872124671936
        },
        {
          "text": "any rights hereunder.",
          "bbox": [
            281.0,
            4236.0,
            709.0,
            4285.0
          ],
          "confidence": 0.9998981952667236
        },
        {
          "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
          "bbox": [
            332.0,
            4437.0,
            1470.0,
            4479.0
          ],
          "confidence": 0.9972561001777649
        }
      ],
      "nearby_headers": [
        {
          "text": "MULTIPLIED BY",
          "page": 13,
          "bbox": [
            450.0,
            755.0,
            843.0,
            793.0
          ]
        },
        {
          "text": "MULTIPLIED BY",
          "page": 13,
          "bbox": [
            290.0,
            1000.0,
            685.0,
            1038.0
          ]
        },
        {
          "text": "ARTICLE 2",
          "page": 13,
          "bbox": [
            1508.0,
            3105.0,
            1791.0,
            3149.0
          ]
        },
        {
          "text": "RIGHTS AND OBLIGATIONS",
          "page": 13,
          "bbox": [
            1281.0,
            3176.0,
            2026.0,
            3218.0
          ]
        }
      ]
    }
  ]
}